C-1 PENTACEL ® Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated...
-
Upload
ernest-baker -
Category
Documents
-
view
229 -
download
7
Transcript of C-1 PENTACEL ® Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated...
C-1
PENTACELPENTACEL®®
Diphtheria and Tetanus Toxoids and Acellular Pertussis Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus Vaccine and HaemophilusAdsorbed, Inactivated Poliovirus Vaccine and Haemophilus b b
Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib Combined)(DTaP-IPV/Hib Combined)
Vaccine and Related Biological Products Vaccine and Related Biological Products Advisory CommitteeAdvisory Committee
January 25, 2007January 25, 2007
The vaccines business of sanofi-aventis GroupThe vaccines business of sanofi-aventis Group
C-2
PENTACEL - AgendaPENTACEL - Agenda
IntroductionIntroduction Luc Kuykens, MD, MPHLuc Kuykens, MD, MPHVP Regulatory AffairsVP Regulatory Affairs
SafetySafety Luc Kuykens, MD, MPHLuc Kuykens, MD, MPHVP Regulatory AffairsVP Regulatory Affairs
Immunogenicity Immunogenicity Michael Decker, MD, MPH Michael Decker, MD, MPH VP Scientific and Medical AffairsVP Scientific and Medical Affairs
Canadian Post-Marketing Canadian Post-Marketing EffectivenessEffectiveness
Scott Halperin, MDScott Halperin, MDProfessor of PediatricsProfessor of PediatricsDalhousie University, Halifax, CanadaDalhousie University, Halifax, Canada
US PerspectiveUS Perspective David Greenberg, MDDavid Greenberg, MDDirector Scientific and Medical AffairsDirector Scientific and Medical Affairs
ConclusionConclusion Luc Kuykens, MD, MPHLuc Kuykens, MD, MPHVP Regulatory AffairsVP Regulatory Affairs
C-3
PENTACEL: First Candidate DTaP-IPV-Hib PENTACEL: First Candidate DTaP-IPV-Hib Combination Vaccine in the USCombination Vaccine in the US
Unique Benefits for Entire Immunization CommunityUnique Benefits for Entire Immunization Community Patient BenefitsPatient Benefits
– Maximum shot reductionMaximum shot reduction
– Well established safety profile; 9 years exclusive useWell established safety profile; 9 years exclusive usein Canadain Canada
Health Care Provider BenefitsHealth Care Provider Benefits– Optimizes implementation of immunization recommendationsOptimizes implementation of immunization recommendations
– Simplifies administrationSimplifies administration
Public Health BenefitsPublic Health Benefits– May improve vaccination coverage rates and timelinessMay improve vaccination coverage rates and timeliness
– Improves combination vaccine supplyImproves combination vaccine supply
C-4
PENTACEL FormulationPENTACEL Formulation
QuadracelQuadracel PENTACELPENTACEL
Tetanus ToxoidTetanus Toxoid 5 Lf5 Lf 5 Lf5 Lf
Diphtheria ToxoidDiphtheria Toxoid 15 Lf15 Lf 15 Lf15 Lf
Pertussis ToxoidPertussis Toxoid 20 20 µgµg 20 20 µµgg
Filamentous HemagglutininFilamentous Hemagglutinin 20 20 µµgg 20 20 µµgg
Pertactin Pertactin 3 3 µµgg 3 3 µµgg
Fimbriae Types 2 and 3Fimbriae Types 2 and 3 5 5 µµgg 5 5 µµgg
IPV Types 1, 2, 3IPV Types 1, 2, 3 40, 8, 32 DAU40, 8, 32 DAU 40, 8, 32 DAU40, 8, 32 DAU
PRP-T (ActHIB)PRP-T (ActHIB) -- 10 10 µµgg
Adjuvant: 0.33 mg aluminum; Adjuvant: 0.33 mg aluminum; 0.6% v/v 0.6% v/v 2-phenoxyethanol2-phenoxyethanol
C-5
Vaccine FormulationVaccine Formulation
PENTACELPENTACEL DaptacelDaptacel AdacelAdacel
Tetanus ToxoidTetanus Toxoid 5 Lf5 Lf 5 Lf5 Lf 5 Lf5 Lf
Diphtheria ToxoidDiphtheria Toxoid 15 Lf15 Lf 15 Lf15 Lf 2 Lf2 Lf
5 Component Pertussis Antigens5 Component Pertussis Antigens
Pertussis ToxoidPertussis Toxoid 20 20 µµgg 10 10 µµgg 2.5 2.5 µµgg
Filamentous HemagglutininFilamentous Hemagglutinin 20 20 µµgg 5 5 µµgg 5 5 µµgg
Pertactin Pertactin 3 3 µµgg 3 3 µµgg 3 3 µµgg
Fimbriae Types 2 and 3Fimbriae Types 2 and 3 5 5 µµgg 5 5 µµgg 5 5 µµgg
IPV Types 1, 2, 3IPV Types 1, 2, 3 40, 8, 32 DAU40, 8, 32 DAU -- --
PRP-TPRP-T 10 10 µµgg -- --
Adjuvant: 0.33 mg aluminum; Adjuvant: 0.33 mg aluminum; 0.6% v/v 0.6% v/v 2-phenoxyethanol2-phenoxyethanol
C-6
Vaccine FormulationVaccine Formulation
PENTACELPENTACEL DaptacelDaptacel AdacelAdacel
Tetanus ToxoidTetanus Toxoid 5 Lf5 Lf 5 Lf5 Lf 5 Lf5 Lf
Diphtheria ToxoidDiphtheria Toxoid 15 Lf15 Lf 15 Lf15 Lf 2 Lf2 Lf
5 Component Pertussis Antigens5 Component Pertussis Antigens
Pertussis ToxoidPertussis Toxoid 20 20 µµgg 10 10 µµgg 2.5 2.5 µµgg
Filamentous HemagglutininFilamentous Hemagglutinin 20 20 µµgg 5 5 µµgg 5 5 µµgg
Pertactin Pertactin 3 3 µµgg 3 3 µµgg 3 3 µµgg
Fimbriae Types 2 and 3Fimbriae Types 2 and 3 5 5 µµgg 5 5 µµgg 5 5 µµgg
IPV Types 1, 2, 3IPV Types 1, 2, 3 40, 8, 32 DAU40, 8, 32 DAU -- --
PRP-TPRP-T 10 10 µµgg -- --
Adjuvant: 0.33 mg aluminum; Adjuvant: 0.33 mg aluminum; 0.6% v/v 0.6% v/v 2-phenoxyethanol2-phenoxyethanol
C-7
Vaccine FormulationVaccine Formulation
PENTACELPENTACEL DaptacelDaptacel AdacelAdacel
Tetanus ToxoidTetanus Toxoid 5 Lf5 Lf 5 Lf5 Lf 5 Lf5 Lf
Diphtheria ToxoidDiphtheria Toxoid 15 Lf15 Lf 15 Lf15 Lf 2 Lf2 Lf
5 Component Pertussis Antigens5 Component Pertussis Antigens
Pertussis ToxoidPertussis Toxoid 20 20 µµgg 10 10 µµgg 2.5 2.5 µµgg
Filamentous HemagglutininFilamentous Hemagglutinin 20 20 µµgg 5 5 µµgg 5 5 µµgg
Pertactin Pertactin 3 3 µµgg 3 3 µµgg 3 3 µµgg
Fimbriae Types 2 and 3Fimbriae Types 2 and 3 5 5 µµgg 5 5 µµgg 5 5 µµgg
IPV Types 1, 2, 3IPV Types 1, 2, 3 40, 8, 32 DAU40, 8, 32 DAU -- --
PRP-TPRP-T 10 10 µµgg -- --
Adjuvant: 0.33 mg aluminum; Adjuvant: 0.33 mg aluminum; 0.6% v/v 0.6% v/v 2-phenoxyethanol2-phenoxyethanol
C-8
Pertussis Antibody Levels vs ProtectionPertussis Antibody Levels vs Protection
Pattern of Antibodies*Pattern of Antibodies* Protective EfficacyProtective Efficacy††
FIMFIM PRNPRN PTPT %%
LowLow LowLow HighHigh 4646
HighHigh LowLow High or LowHigh or Low 7272
LowLow HighHigh High or LowHigh or Low 7575
HighHigh HighHigh High or LowHigh or Low 8585
*High (*High (>>5 units) or Low (0 to <5 units) levels of antibody before pertussis exposure.5 units) or Low (0 to <5 units) levels of antibody before pertussis exposure.††Efficacy against WHO-defined pertussis. Storsaeter et al. Efficacy against WHO-defined pertussis. Storsaeter et al. Vaccine.Vaccine. 1998;16:1907-16. 1998;16:1907-16.
C-9
PENTACEL Clinical Development ProgramPENTACEL Clinical Development Program
Demonstration of safety and immunogenicityDemonstration of safety and immunogenicity– Comparison to the standard of careComparison to the standard of care
– Comparison of 3 consistency lotsComparison of 3 consistency lots
– Concomitant administration of other Concomitant administration of other recommended vaccinesrecommended vaccines
– Comparison Comparison of a 4of a 4thth dose dose when administered at when administered at 15 to 16 vs 17 to 18 months of age15 to 16 vs 17 to 18 months of age
Immunogenicity of PENTACEL compared to Immunogenicity of PENTACEL compared to Daptacel Daptacel in the in the Sweden I Efficacy StudySweden I Efficacy Study
C-10
PENTACEL Clinical Studies for US LicensurePENTACEL Clinical Studies for US Licensure††
Total number of PENTACEL recipients: Total number of PENTACEL recipients: 71467146
StudyStudy PurposePurpose NN PENTACELPENTACEL
P3T06P3T06 PENTACEL vs Standard of Care (SC) PENTACEL vs Standard of Care (SC) (Daptacel, IPOL, ActHIB) (Daptacel, IPOL, ActHIB) 1939 1939 485 485
494-01494-01 Lot consistency, PENTACEL vs Lot consistency, PENTACEL vs Formulation Equivalent (FE) Formulation Equivalent (FE) (HCPDT, Poliovax, ActHIB)(HCPDT, Poliovax, ActHIB)
35383538 25062506
M5A07M5A07 Interaction with PrevnarInteraction with Prevnar(Infant Series)(Infant Series) 11661166 11661166
494-03494-03 Interaction with Prevnar, MMR and Interaction with Prevnar, MMR and Varivax vaccines (4Varivax vaccines (4thth Dose) Dose) 12071207 12071207
5A99085A9908 Administration at 15-16 vs 17-18Administration at 15-16 vs 17-18months of agemonths of age 17821782 17821782
††All subjects who received at least one doseAll subjects who received at least one dose
C-11
Composition of Studied VaccinesComposition of Studied Vaccines
Standard of Care (SC)Standard of Care (SC) Formulation Equivalent (FE)Formulation Equivalent (FE)
AntigenAntigen PENTACELPENTACEL DaptacelDaptacel IPOLIPOL ActHIBActHIB HCPDTHCPDT†† PoliovaxPoliovax ActHIBActHIB
Diphtheria ToxoidDiphtheria Toxoid 15 Lf15 Lf 15 Lf15 Lf 15 Lf15 Lf
Tetanus ToxoidTetanus Toxoid 5 Lf5 Lf 5 Lf5 Lf 5 Lf5 Lf
PTPT 20 20 µµgg 10 10 µµgg 20 20 µµgg
FHAFHA 20 20 µµgg 5 5 µµgg 20 20 µµgg
PRNPRN 3 3 µµgg 3 3 µµgg 3 3 µµgg
FIM FIM 5 5 µµgg 5 5 µµgg 5 5 µµgg
Poliovirus Type 1Poliovirus Type 1 40 DAU40 DAU 40 DAU40 DAU 40 DAU40 DAU
Poliovirus Type 2Poliovirus Type 2 8 DAU8 DAU 8 DAU8 DAU 8 DAU8 DAU
Poliovirus Type 3Poliovirus Type 3 32 DAU32 DAU 32 DAU32 DAU 32 DAU32 DAU
PRP-TPRP-T 10 10 µµgg 10 10 µµgg 10 10 µµgg
††PENTACEL formulation componentPENTACEL formulation component
C-12
SafetySafety ImmunogenicityImmunogenicity††
StudyStudy PENTACELPENTACEL ControlControl PENTACELPENTACEL ControlControl
P3T06P3T06 485485 14541454 374374 11671167
494-01494-01 25062506 10321032 11361136 403403
494-03494-03 12071207 NANA 274274 NANA
M5A07M5A07 NANA NANA 886886 NANA
TotalTotal 41984198 24862486 26702670 15701570
Overall Summary (Infant Series): Overall Summary (Infant Series): Safety and Immunogenicity PopulationsSafety and Immunogenicity Populations
††Per-protocol populationPer-protocol population
C-13
SafetySafety ImmunogenicityImmunogenicity††
StudyStudy PENTACELPENTACEL ControlControl PENTACELPENTACEL ControlControl
P3T06P3T06 431431 418418 371371 349349
494-01494-01 18621862 739739 883883 291291
494-03494-03 958958 NANA 819819 NANA
5A99085A9908 17821782 NANA 735735 NANA
TotalTotal 50335033 11571157 28082808 640640
Overall Summary (4Overall Summary (4thth Dose): Dose): Safety and Immunogenicity PopulationsSafety and Immunogenicity Populations
††Per-protocol populationPer-protocol population
C-14
PENTACEL Key FindingsPENTACEL Key Findings
Comparable immunogenicity to standard of care Comparable immunogenicity to standard of care
Safety profile similar to separate vaccines Safety profile similar to separate vaccines
Can be given concomitantly with other Can be given concomitantly with other recommended vaccinesrecommended vaccines
In Canada, where PENTACEL was introduced in In Canada, where PENTACEL was introduced in 1997 and is used universally1997 and is used universally– Invasive Hib disease remains rareInvasive Hib disease remains rare
– Rates of pertussis have decreased among children Rates of pertussis have decreased among children aged 1-9 yearsaged 1-9 years
C-15
PENTACEL - AgendaPENTACEL - Agenda
IntroductionIntroduction Luc Kuykens, MD, MPHLuc Kuykens, MD, MPHVP Regulatory AffairsVP Regulatory Affairs
SafetySafety Luc Kuykens, MD, MPHLuc Kuykens, MD, MPHVP Regulatory AffairsVP Regulatory Affairs
Immunogenicity Immunogenicity Michael Decker, MD, MPH Michael Decker, MD, MPH VP Scientific and Medical AffairsVP Scientific and Medical Affairs
Canadian Post-Marketing Canadian Post-Marketing EffectivenessEffectiveness
Scott Halperin, MDScott Halperin, MDProfessor of PediatricsProfessor of PediatricsDalhousie University, Halifax, CanadaDalhousie University, Halifax, Canada
US PerspectiveUS Perspective David Greenberg, MDDavid Greenberg, MDDirector Scientific and Medical AffairsDirector Scientific and Medical Affairs
ConclusionConclusion Luc Kuykens, MD, MPHLuc Kuykens, MD, MPHVP Regulatory AffairsVP Regulatory Affairs
C-16
Safety ObjectivesSafety Objectives
Compare safety of PENTACEL against safety of Compare safety of PENTACEL against safety of control vaccinescontrol vaccines
Assess safety of PENTACEL with or without Assess safety of PENTACEL with or without other recommended vaccinesother recommended vaccines
Safety Population: defined as those who had at Safety Population: defined as those who had at least 1 scheduled dose of study vaccinesleast 1 scheduled dose of study vaccines
C-17
Infant Series and 4Infant Series and 4thth Dose: Safety Profile Dose: Safety Profile
Immediate Reactions Immediate Reactions
– 30 minutes post-vaccination30 minutes post-vaccination
Solicited Local and Systemic ReactionsSolicited Local and Systemic Reactions
Non-Serious Unsolicited Adverse EventsNon-Serious Unsolicited Adverse Events
Events of Special InterestEvents of Special Interest
Serious Adverse EventsSerious Adverse Events
C-18
Infant SeriesInfant Series: Immediate Reactions : Immediate Reactions
Controlled StudiesControlled StudiesNon-controlled Non-controlled
StudiesStudies
PENTACELPENTACEL494-01, P3T06494-01, P3T06
N=2293N=2293SCSC
N=418N=418FEFE
N=739N=739
PENTACELPENTACEL494-03, 5A9908494-03, 5A9908
N=2740N=2740
nn %% nn %% nn %% nn %%
Total participants with at Total participants with at least one reactionleast one reaction 11 <0.1<0.1 33 0.20.2 11 0.10.1 00 0.00.0
UrticariaUrticaria 11 <0.1<0.1 00 0.00.0 00 0.00.0 00 0.00.0
Allergic reactionAllergic reaction 00 0.00.0 11 0.10.1 00 0.00.0 00 0.00.0
CryingCrying 00 0.00.0 11 0.10.1 00 0.00.0 00 0.00.0
ErythemaErythema 00 0.00.0 11 0.10.1 00 0.00.0 00 0.00.0
DiarrheaDiarrhea 00 0.00.0 00 0.00.0 11 0.10.1 00 0.00.0
IrritabilityIrritability 00 0.00.0 11 0.10.1 00 0.00.0 00 0.00.0
C-19
44thth Dose: Dose: Immediate ReactionsImmediate Reactions
Controlled StudiesControlled StudiesNon-controlled Non-controlled
StudiesStudies
PENTACELPENTACEL494-01, P3T06494-01, P3T06
N=2293N=2293SCSC
N=418N=418FEFE
N=739N=739
PENTACELPENTACEL494-03, 5A9908494-03, 5A9908
N=2740N=2740
nn %% nn %% nn %% nn %%
Total participants with at least one reaction 22 0.10.1 11 0.20.2 00 0.00.0 3131 1.11.1
Injection site erythemaInjection site erythema 22 0.10.1 00 0.00.0 00 0.00.0 2424 0.90.9
Injection site bruisingInjection site bruising 00 0.00.0 00 0.00.0 00 0.00.0 22 0.10.1
Injection site burningInjection site burning 00 0.00.0 00 0.00.0 00 0.00.0 11 <0.1<0.1
Injection site indurationInjection site induration 00 0.00.0 11 0.20.2 00 0.00.0 11 <0.1<0.1
Injection site irritationInjection site irritation 00 0.00.0 00 0.00.0 00 0.00.0 11 <0.1<0.1
Local edema upper limbLocal edema upper limb 00 0.00.0 00 0.00.0 00 0.00.0 11 <0.1<0.1
DermatitisDermatitis 00 0.00.0 00 0.00.0 00 0.00.0 11 <0.1<0.1
Mottled skinMottled skin 00 0.00.0 00 0.00.0 00 0.00.0 11 <0.1<0.1
UrticariaUrticaria 00 0.00.0 00 0.00.0 00 0.00.0 11 <0.1<0.1
NasopharyngitisNasopharyngitis 00 0.00.0 00 0.00.0 00 0.00.0 11 <0.1<0.1
TremorTremor 00 0.00.0 00 0.00.0 00 0.00.0 11 <0.1<0.1
C-20
Infant Series and 4Infant Series and 4thth Dose: Safety Profile Dose: Safety Profile
Immediate Reactions Immediate Reactions
Solicited Local Solicited Local and Systemicand Systemic Reactions Reactions
– Redness, swelling, tenderness, and change in limb Redness, swelling, tenderness, and change in limb circumference (4circumference (4thth dose, only) collected on diary cards, dose, only) collected on diary cards,days 0-7, severity documenteddays 0-7, severity documented
Non-Serious Unsolicited Adverse EventsNon-Serious Unsolicited Adverse Events
Events of Special InterestEvents of Special Interest
Serious Adverse EventsSerious Adverse Events
C-21
Infant Series:Infant Series: Solicited Local Reactions After Solicited Local Reactions After PENTACEL, Days 0-7, Any DosePENTACEL, Days 0-7, Any Dose
00
2020
4040
6060
8080
100100
00 11 22 33 44 55 66 77
DaysDays
Per
cen
tP
erce
nt
RednessRedness SwellingSwelling TendernessTenderness
C-22
44thth Dose: Dose: Solicited Local Reactions After Solicited Local Reactions After PENTACEL, Days 0-7PENTACEL, Days 0-7
00
2020
4040
6060
8080
100100
Per
cen
tP
erce
nt
00 11 22 33 44 55 66 77
DaysDays
RednessRedness SwellingSwelling TendernessTenderness
C-23
Infant Series: Solicited Local Reactions After Infant Series: Solicited Local Reactions After PENTACEL, Days 0-3PENTACEL, Days 0-3, by Dose, by Dose
TendernessTendernessSwellingSwellingRednessRedness
AnyAny 5.7 5.7 4.8 4.8 4.8 4.8 5.6 5.6 3.8 3.8 2.8 2.8 44.2 44.2 36.4 36.4 37.4 37.4
MildMild 3.9 3.9 4.0 4.0 3.9 3.9 3.2 3.2 2.8 2.8 2.1 2.1 25.6 25.6 26.2 26.2 27.3 27.3
ModerateModerate 1.4 1.4 0.6 0.6 0.9 0.9 1.8 1.8 0.8 0.8 0.7 0.7 14.0 14.0 7.9 7.9 8.3 8.3
SevereSevere 0.4 0.4 0.1 0.1 0.1 0.1 0.5 0.5 0.2 0.2 0.0 0.0 4.6 4.6 2.2 2.2 1.9 1.9
5.7 4.8 4.8 5.6 3.8 2.8
44.236.4 37.4
0
20
40
60
80
100
Dose 1
Pe
rce
nt
Dose 2 Dose 3 Dose 1 Dose 2 Dose 3 Dose 1 Dose 2 Dose 3
Mild Moderate Severe
C-24
Infant Series: Solicited Local Swelling, Infant Series: Solicited Local Swelling, Days 0-3, Comparison to ControlsDays 0-3, Comparison to Controls†† by Dose by Dose
††Percentages are based on the most severe reaction at any of the vaccination sites for the individual control vaccinesPercentages are based on the most severe reaction at any of the vaccination sites for the individual control vaccines
10
20
30
40
50
Per
cen
t
Dose 1 Dose 2 Dose 3 Dose 1 Dose 2 Dose 3 Dose 1 Dose 2 Dose 3 Dose 1 Dose 2 Dose 3
PENTACELPENTACEL494-01, P3T06494-01, P3T06
SCSC
Controlled StudiesControlled Studies
0
AnyAny 5.35.3 3.93.9 2.72.7 6.06.0 5.25.2 7.87.8 7.17.1 4.04.0 3.33.3 6.5 6.5 3.3 3.3 3.13.1
MildMild 3.23.2 3.13.1 2.02.0 3.63.6 4.34.3 6.56.5 5.85.8 3.43.4 3.03.0 3.33.3 2.12.1 2.32.3
ModerateModerate 1.61.6 0.80.8 0.70.7 2.02.0 0.90.9 1.21.2 1.21.2 0.50.5 0.30.3 2.42.4 0.60.6 0.70.7
SevereSevere 0.40.4 0.00.0 0.00.0 0.40.4 0.10.1 0.10.1 0.10.1 0.10.1 0.00.0 0.80.8 0.50.5 0.10.1
3.13.13.3 3.3 6.5 6.5
3.33.34.04.07.17.17.87.8
5.25.26.06.02.72.73.93.9
5.35.3
PENTACELPENTACEL494-03494-03
FEFE
Mild Moderate Severe
C-25
44thth Dose: Solicited Local Swelling, Dose: Solicited Local Swelling, Days 0-3, Comparison to ControlsDays 0-3, Comparison to Controls††
PENTACEL 494-01, P3T06
SC FE PENTACEL 494-03, 5A9908
0
10
20
30
40
50
Per
cen
t
Mild Moderate Severe
††Percentages are based on the most severe reaction at any of the vaccination sites for the individual control vaccinesPercentages are based on the most severe reaction at any of the vaccination sites for the individual control vaccines
AnyAny 11.311.3 11.611.6 13.913.9 16.016.0
MildMild 6.96.9 7.77.7 9.29.2 6.66.6
ModerateModerate 3.23.2 2.62.6 3.53.5 7.97.9
SevereSevere 1.21.2 1.31.3 1.31.3 1.61.6
16.016.013.913.9
11.611.611.311.3
Controlled StudiesControlled Studies
C-26
44thth Dose: Change in Limb Circumference, Dose: Change in Limb Circumference,Days 0-3, Comparison to ControlDays 0-3, Comparison to Control††
PENTACEL 494-01, P3T06
SC HCPDT PENTACEL 494-03, 5A9908
0
10
20
30
40
50
Per
cen
t
Mild Moderate Severe
††Percentages are based on the most severe reaction at any of the vaccination sites for the individual control vaccinesPercentages are based on the most severe reaction at any of the vaccination sites for the individual control vaccines
AnyAny 27.027.0 37.537.5 21.721.7 34.434.4
MildMild 22.322.3 28.228.2 18.518.5 26.626.6
ModerateModerate 4.54.5 8.28.2 3.13.1 7.07.0
SevereSevere 0.30.3 1.11.1 0.00.0 0.80.8
34.434.4
21.721.7
37.537.5
27.027.0
Controlled StudiesControlled Studies
C-27
Infant Series and 4Infant Series and 4thth Dose: Safety Profile Dose: Safety Profile
Immediate Reactions Immediate Reactions
Solicited Solicited Local andLocal and Systemic Reactions Systemic Reactions
– Fever, less active, crying, fussiness, vomiting, diarrhea, Fever, less active, crying, fussiness, vomiting, diarrhea, anorexia and rash (presence or absence) collected on diary anorexia and rash (presence or absence) collected on diary cards, days 0-7, severity documented cards, days 0-7, severity documented
Non-Serious Unsolicited Adverse EventsNon-Serious Unsolicited Adverse Events
Events of Special InterestEvents of Special Interest
Serious Adverse EventsSerious Adverse Events
C-28
Infant Series: Solicited Fever After Infant Series: Solicited Fever After PENTACEL, Day 0-7PENTACEL, Day 0-7, Any Dose, Any Dose
0
10
20
30
40
50
0 1 2 3 4 5 6 7
Days
Per
cen
t
Fever
C-29
Infant Series: Solicited Fever, Days 0-3, Infant Series: Solicited Fever, Days 0-3, Comparison to Controls by DoseComparison to Controls by Dose
10
20
30
40
50
Per
cen
t
0
Mild Moderate Severe
PENTACELPENTACEL494-01, P3T06494-01, P3T06
SCSC FEFE PENTACELPENTACEL494-03494-03
Controlled StudiesControlled Studies
AnyAny 7.77.7 13.713.7 18.718.7 9.39.3 16.116.1 15.815.8 13.813.8 15.715.7 20.620.6 11.5 11.5 16.5 16.5 18.418.4
MildMild 6.26.2 10.410.4 12.912.9 7.77.7 11.811.8 10.710.7 11.511.5 10.810.8 16.016.0 10.010.0 12.712.7 13.913.9
ModerateModerate 1.11.1 3.13.1 5.15.1 1.51.5 3.93.9 4.84.8 2.22.2 4.34.3 3.93.9 1.51.5 3.43.4 4.04.0
SevereSevere 0.40.4 0.20.2 0.70.7 0.10.1 0.40.4 0.30.3 0.10.1 0.60.6 0.70.7 0.00.0 0.40.4 0.50.5
Dose 1 Dose 2 Dose 3 Dose 1 Dose 2 Dose 3 Dose 1 Dose 2 Dose 3 Dose 1 Dose 2 Dose 3
18.418.416.5 16.5
11.5 11.5
20.620.6
15.715.713.813.8
15.815.816.116.1
9.39.3
18.718.7
13.713.7
7.77.7
PENTACELPENTACEL494-03494-03
C-30
Infant Series: Infant Series: Non-Inferiority of Fever Non-Inferiority of Fever Rates, Rates, Days 0-3, Days 0-3, 90% CI of Difference (PENTACEL minus Control) by Dose90% CI of Difference (PENTACEL minus Control) by Dose
Within LimitWithin Limit Outside LimitOutside Limit
-10-10 -8-8 00 1010 1212 1414-2-2 22 44-4-4-6-6 66 88
P3T06P3T06
1st Dose1st Dose-3.49-3.49
3rd Dose3rd Dose0.560.56
2nd Dose2nd Dose-5.26-5.26
494-01494-01
-1.40-1.402nd Dose2nd Dose
-1.33-1.333rd Dose3rd Dose
1st Dose1st Dose-5.70-5.70
C-31
44thth Dose: Solicited Fever After PENTACEL, Dose: Solicited Fever After PENTACEL, Days 0-7 Days 0-7
0
10
20
30
40
50
0 1 2 3 4 5 6 7
Days
Per
cen
t
Fever
C-32
44thth Dose: Solicited Fever, Days 0-3, Dose: Solicited Fever, Days 0-3,Comparison to ControlsComparison to Controls
PENTACEL 494-01, P3T06
SC FE PENTACEL 494-03, 5A9908
0
10
20
30
40
50
Per
cen
t
Mild Moderate Severe
AnyAny 11.211.2 8.78.7 13.113.1 14.514.5
MildMild 8.18.1 5.55.5 9.19.1 9.39.3
ModerateModerate 2.52.5 2.42.4 3.53.5 4.34.3
SevereSevere 0.60.6 0.80.8 0.50.5 0.80.8
14.514.513.113.1
8.78.711.211.2
Controlled StudiesControlled Studies
C-33
44thth Dose: Dose: Non-Inferiority of Fever Non-Inferiority of Fever Rates, Rates, Days 0-3, Days 0-3, 90% CI of Difference (PENTACEL minus Control)90% CI of Difference (PENTACEL minus Control)
Within LimitWithin Limit Outside LimitOutside Limit
-10-10 -8-8 00 1010 1212 1414-2-2 22 44-4-4-6-6 66 88
494-01494-01-2.42-2.42
P3T06P3T064.664.66
C-34
Infant Series and 4Infant Series and 4thth Dose: Safety Profile Dose: Safety Profile
Immediate ReactionsImmediate Reactions
Solicited Local and Systemic ReactionsSolicited Local and Systemic Reactions
Non-Serious Unsolicited Adverse EventsNon-Serious Unsolicited Adverse Events
– Any non-serious Any non-serious unsolicited unsolicited event, event, days 0-7, days 0-7, severity documentedseverity documented
– Any non-seriousAny non-serious event requiring healthcare provider event requiring healthcare provider contact,contact, days 8-60, severity documented days 8-60, severity documented
Events of Special InterestEvents of Special Interest
Serious Adverse EventsSerious Adverse Events
C-35
Infant Series and 4Infant Series and 4thth Dose: Dose: Non-serious Non-serious Unsolicited Adverse EventsUnsolicited Adverse Events
No difference in rates between PENTACEL No difference in rates between PENTACEL and control groups for frequently reported and control groups for frequently reported and rare eventsand rare events
Most events were common childhood Most events were common childhood conditions such as URI, otitis media, teething conditions such as URI, otitis media, teething and nasal congestionand nasal congestion
Majority assessed as non-related by Majority assessed as non-related by the investigatorsthe investigators
C-36
Infant Series and 4Infant Series and 4thth Dose: Safety Profile Dose: Safety Profile
Immediate ReactionsImmediate Reactions
Solicited Local and Systemic ReactionsSolicited Local and Systemic Reactions
Non-Serious Unsolicited Adverse EventsNon-Serious Unsolicited Adverse Events
Events of Special InterestEvents of Special Interest
– Hypotonic-hyporesponsive episode (HHE), hypotonia, Hypotonic-hyporesponsive episode (HHE), hypotonia, non-febrile seizure, febrile seizure, and possible seizure non-febrile seizure, febrile seizure, and possible seizure collected days 0-60, severity documentedcollected days 0-60, severity documented
Serious Adverse EventsSerious Adverse Events
C-37
Infant Series: Events of Special Interest, Infant Series: Events of Special Interest, Days 0-7, Comparison to Controls After Any DoseDays 0-7, Comparison to Controls After Any Dose
P3T06P3T06 494-01494-01 494-03494-03
PENTACELPENTACELN=485N=485
StandardStandardof Careof CareN=1454N=1454
PENTACELPENTACELN=2506N=2506
Formulation Formulation EquivalentEquivalent
N=1032N=1032PENTACELPENTACEL
N=1207N=1207
nn %% nn %% nn %% nn %% nn %%
HHEHHE 00 0.00.0 00 0.00.0 00 0.00.0 00 0.00.0 00 0.00.0
HypotoniaHypotonia 00 0.00.0 11 0.10.1 33 0.10.1 00 0.00.0 11 0.10.1
Non-Febrile SeizureNon-Febrile Seizure 00 0.00.0 11 0.10.1 11 <0.1<0.1 11 0.10.1 00 0.00.0
Febrile SeizureFebrile Seizure 00 0.00.0 00 0.00.0 00 0.00.0 00 0.00.0 00 0.00.0
Possible SeizurePossible Seizure 00 0.00.0 00 0.00.0 11 <0.1<0.1 00 0.00.0 00 0.00.0
C-38
44thth Dose Dose: : Events of Special Interest, Events of Special Interest, Days 0-7, Comparison to ControlDays 0-7, Comparison to Control
P3T06P3T06 494-01494-01 494-03494-03 5A99085A9908
PENTACELPENTACELN=431N=431
Standard Standard of Careof CareN=418N=418
PENTACELPENTACELN=1862N=1862
Formulation Formulation EquivalentEquivalent
N=739N=739PENTACELPENTACEL
N=958N=958PENTACELPENTACEL
N=1782N=1782
nn %% nn %% nn %% nn %% nn %% nn %%
HHEHHE 00 0.00.0 00 0.00.0 00 0.00.0 00 0.00.0 00 0.00.0 00 0.00.0
HypotoniaHypotonia 00 0.00.0 00 0.00.0 00 0.00.0 00 0.00.0 00 0.00.0 00 0.00.0
Non-Febrile Non-Febrile SeizureSeizure 00 0.00.0 00 0.00.0 00 0.00.0 00 0.00.0 00 0.00.0 00 0.00.0
Febrile SeizureFebrile Seizure 00 0.00.0 00 0.00.0 00 0.00.0 22 0.30.3 00 0.00.0 22 0.10.1
Possible SeizurePossible Seizure 00 0.00.0 00 0.00.0 00 0.00.0 00 0.00.0 00 0.00.0 00 0.00.0
C-39
Infant Series and 4Infant Series and 4thth Dose: Safety Profile Dose: Safety Profile
Immediate ReactionsImmediate Reactions
Solicited Local and Systemic ReactionsSolicited Local and Systemic Reactions
Non-Serious Unsolicited Adverse EventsNon-Serious Unsolicited Adverse Events
Events of Special InterestEvents of Special Interest
Serious Adverse EventsSerious Adverse Events
– Any serious adverse event during the study through Day 60 Any serious adverse event during the study through Day 60 post-dose 3 or post-dose 4 (Day 180 for P3T06), post-dose 3 or post-dose 4 (Day 180 for P3T06), severity documentedseverity documented
C-40
Infant Series: Serious Adverse Events, Infant Series: Serious Adverse Events, Days 0-60, Comparison to Control After Any DoseDays 0-60, Comparison to Control After Any Dose
P3T06P3T06 494-01494-01 494-03494-03
PENTACELPENTACELN=485N=485
Standard Standard of Careof CareN=1454N=1454
PENTACELPENTACELN=2506N=2506
Formulation Formulation EquivalentEquivalent
N=1032N=1032PENTACELPENTACEL
N=1207N=1207
nn %% nn %% nn %% nn %% nn %%
Total participants with at least one SAE 2525 5.25.2 7575 5.25.2 3838 1.51.5 1717 1.61.6 4949 4.14.1
Total participants with at least one related SAE elated SAE
00 0.00.0 11 0.10.1 00 0.00.0 00 0.00.0 00 0.00.0
C-41
Infant Series: Related Serious Adverse Events Infant Series: Related Serious Adverse Events After Any DoseAfter Any Dose
No SAEs were reported as related to PENTACELNo SAEs were reported as related to PENTACEL
A 7-week-old female (Study P3T06) experienced non-A 7-week-old female (Study P3T06) experienced non-febrile seizure with apnea 12 hours post-Dose 1 of febrile seizure with apnea 12 hours post-Dose 1 of Daptacel, ActHIB, IPOL. Recombivax and Prevnar were Daptacel, ActHIB, IPOL. Recombivax and Prevnar were co-administered. The event was considered probably co-administered. The event was considered probably related to vaccinationrelated to vaccination
C-42
Infant Series: DeathsInfant Series: Deaths
A total of 3 deaths occurred during the Infant Series:A total of 3 deaths occurred during the Infant Series:– A 2-month-old female (Study 494-03, PENTACEL) died following A 2-month-old female (Study 494-03, PENTACEL) died following
an automobile accident, 22 days post-Dose 1an automobile accident, 22 days post-Dose 1
– A 4-month-old male (Study 494-03, PENTACEL) died 52 days A 4-month-old male (Study 494-03, PENTACEL) died 52 days post-Dose 1. Cause of death reported as Sudden Infant post-Dose 1. Cause of death reported as Sudden Infant Death SyndromeDeath Syndrome
– An 8-month-old female (Study P3T06, SC) developed symptoms An 8-month-old female (Study P3T06, SC) developed symptoms 54 days post-Dose 3 and was diagnosed with ependymoma. 54 days post-Dose 3 and was diagnosed with ependymoma. Death occurred 222 days post-Dose 3; primary cause of death Death occurred 222 days post-Dose 3; primary cause of death reported as aspirationreported as aspiration
All deaths were considered unrelated to vaccinationAll deaths were considered unrelated to vaccination
C-43
44thth Dose: Serious Adverse EventsDose: Serious Adverse Events
P3T06P3T06 494-01494-01 494-03494-03 5A99085A9908
PENTACELPENTACELN=431N=431
Standard Standard of Careof CareN=418N=418
PENTACELPENTACELN=1862N=1862
FormulationFormulationEquivalentEquivalent
N=739N=739PENTACELPENTACEL
N=958N=958PENTACELPENTACEL
N=1782N=1782
nn %% nn %% nn %% nn %% nn %% nn %%
0-60 days0-60 days 99 2.12.1 77 1.71.7 77 0.40.4 44 0.50.5 1111 1.11.1 2929 1.61.6
61-180 days61-180 days 99†† 2.12.1 22 0.50.5 NANA NANA NANA NANA
No SAEs were reported as related to PENTACEL or No SAEs were reported as related to PENTACEL or Control vaccinesControl vaccines
††Upper respiratory infections (3), congenital malformations (2), reaction to antibiotic, Upper respiratory infections (3), congenital malformations (2), reaction to antibiotic, reaction to insect bite, post-infection cerebellar ataxia, seizurereaction to insect bite, post-infection cerebellar ataxia, seizure
C-44
44thth Dose: Deaths Dose: Deaths
One death occurred after Day 60 of the Infant Series One death occurred after Day 60 of the Infant Series and before the administration of the 4and before the administration of the 4thth dose dose– A 9-month-old male (Study 494-01, PENTACEL) developed A 9-month-old male (Study 494-01, PENTACEL) developed
symptoms 95 days post-Dose 3. Subject was later diagnosed symptoms 95 days post-Dose 3. Subject was later diagnosed with neuroblastoma, which eventually led to death 256 days with neuroblastoma, which eventually led to death 256 days post-Dose 3post-Dose 3
One death occurred after administration of the 4th doseOne death occurred after administration of the 4th dose– A 15-month-old male (Study P3T06, PENTACEL) died 9 days A 15-month-old male (Study P3T06, PENTACEL) died 9 days
post-Dose 4. Cause of death reported as suffocationpost-Dose 4. Cause of death reported as suffocation
Both deaths were considered unrelated to vaccinationBoth deaths were considered unrelated to vaccination
C-45
Canadian Canadian Post-Marketing Safety Post-Marketing Safety
Experience with PENTACEL Experience with PENTACEL
C-46
Canadian Post-Marketing Safety Experience Canadian Post-Marketing Safety Experience
Introduced in May 1997, exclusively used Introduced in May 1997, exclusively used since 1998since 1998
More than 12 million doses distributedMore than 12 million doses distributed
Similar dosing schedule as proposed for USSimilar dosing schedule as proposed for US
Passive surveillance data from spontaneous Passive surveillance data from spontaneous reports to sanofi pasteurreports to sanofi pasteur
C-47
Canadian Post-Marketing Safety Experience: Canadian Post-Marketing Safety Experience: Reported Events Reported Events
288 reports received from May 1997 through 288 reports received from May 1997 through April 2006April 2006– 221 were non-serious221 were non-serious
Most commonly reported adverse events were Most commonly reported adverse events were injection site reactions injection site reactions
C-48
Post-marketing Experience: Most Frequently Reported Post-marketing Experience: Most Frequently Reported Adverse Events Following PENTACEL VaccinationAdverse Events Following PENTACEL Vaccination
MedDRA AE Preferred TermMedDRA AE Preferred Term11 Number of AEs Number of AEs 22
Injection site reactionInjection site reaction 6565
PyrexiaPyrexia 6464
CryingCrying 5151
Injection site inflammationInjection site inflammation 3535
IrritabilityIrritability 3131
UrticariaUrticaria 2525
VomitingVomiting 2424
RashRash 2020
ConvulsionConvulsion33 1919
Injection site massInjection site mass 1616
1MedDRA coding dictionary version 9.02AE: adverse event. Includes both medically-confirmed and consumer cases3Includes MedDRA PT terms of Convulsion, Febrile convulsion, Status epilepticus and Convulsion local
C-49
Distribution of Spontaneously Reported Events Distribution of Spontaneously Reported Events of Special Interest*of Special Interest*
Total reports Total reports received received
N=288**N=288**
Post-Post-Dose 1Dose 1
Post-Post-Dose 2Dose 2
Post-Post-Dose 3Dose 3
Post-Post-Dose 4Dose 4
Post-Post-Any DoseAny Dose
nn nn nn nn nn
HHEsHHEs1,41,4 88 44 00 00 1212
All SeizuresAll Seizures2,42,4 33 66 22 88 1919
Febrile SeizuresFebrile Seizures44 00 00 00 22 22
EncephalopathyEncephalopathy44 11 11 00 11 33
Fatal ReportsFatal Reports3,43,4 1010 11 00 33 1414
* For the period 1 May 1997 and 30 April 2006.**Medically-confirmed and consumer reports1Reported as HHE, or where the symptoms reported corresponded to the definition used for an HHE2MedDRA PT terms of Convulsion, Febrile convulsion, Status epilepticus and Convulsion local3Includes SIDS, Death Due to Unknown cause, and Death Due to Known Cause4For instances where dose information was not provided, the dose number was assumed based on the patient’s age and the latency to the event.
C-50
Safety ConclusionsSafety Conclusions
Safety profile of PENTACEL is similar to that of the Safety profile of PENTACEL is similar to that of the separate administration of standard of care vaccines separate administration of standard of care vaccines (Daptacel, IPOL, and ActHIB) or formulation-equivalent (Daptacel, IPOL, and ActHIB) or formulation-equivalent component vaccines (HCPDT, Poliovax, and ActHIB) component vaccines (HCPDT, Poliovax, and ActHIB)
PENTACEL is safe when administered alone or PENTACEL is safe when administered alone or concomitantly with other age-recommended vaccinesconcomitantly with other age-recommended vaccines
No unexpected safety signals were identified in the No unexpected safety signals were identified in the Canadian post-marketing safety experience, which Canadian post-marketing safety experience, which confirms conclusions from clinical trialsconfirms conclusions from clinical trials
C-51
PENTACEL - AgendaPENTACEL - Agenda
IntroductionIntroduction Luc Kuykens, MD, MPHLuc Kuykens, MD, MPHVP Regulatory AffairsVP Regulatory Affairs
SafetySafety Luc Kuykens, MD, MPHLuc Kuykens, MD, MPHVP Regulatory AffairsVP Regulatory Affairs
Immunogenicity Immunogenicity Michael Decker, MD, MPH Michael Decker, MD, MPH VP Scientific and Medical AffairsVP Scientific and Medical Affairs
Canadian Post-Marketing Canadian Post-Marketing EffectivenessEffectiveness
Scott Halperin, MDScott Halperin, MDProfessor of PediatricsProfessor of PediatricsDalhousie University, Halifax, CanadaDalhousie University, Halifax, Canada
US PerspectiveUS Perspective David Greenberg, MDDavid Greenberg, MDDirector Scientific and Medical AffairsDirector Scientific and Medical Affairs
ConclusionConclusion Luc Kuykens, MD, MPHLuc Kuykens, MD, MPHVP Regulatory AffairsVP Regulatory Affairs
C-52
Immunological Endpoints and AnalysesImmunological Endpoints and Analyses
Geometric Mean Titers (GMT)Geometric Mean Titers (GMT)– A primary endpoint for all antigensA primary endpoint for all antigens
4-Fold Rise (from pre-Dose 1)4-Fold Rise (from pre-Dose 1)– A primary endpoint for pertussis antigensA primary endpoint for pertussis antigens
Seroprotection (Seroprotection (post-Dose threshold)post-Dose threshold)– A primary endpoint for Diphtheria, Tetanus, Hib, PolioA primary endpoint for Diphtheria, Tetanus, Hib, Polio
Vaccine Response (Vaccine Response (cutoff point and cutoff point and baseline)baseline)– All pertussis antigensAll pertussis antigens
Reverse Cumulative Distribution Curves (RCDC)Reverse Cumulative Distribution Curves (RCDC)– All antigensAll antigens
Serological bridge to efficacySerological bridge to efficacy– All pertussis antigensAll pertussis antigens
C-53
Immunogenicity Presentation Sequence Immunogenicity Presentation Sequence
Pertussis ImmunogenicityPertussis Immunogenicity
Hib (PRP) ImmunogenicityHib (PRP) Immunogenicity
Diphtheria and Tetanus ImmunogenicityDiphtheria and Tetanus Immunogenicity
Polio ImmunogenicityPolio Immunogenicity
Co-Administration with Other Licensed VaccinesCo-Administration with Other Licensed Vaccines
C-54
P3T06: PENTACEL vs US Standard of Care Vaccines P3T06: PENTACEL vs US Standard of Care Vaccines Study CharacteristicsStudy Characteristics
Multi-center, randomized, controlled, Multi-center, randomized, controlled, open-label studyopen-label study – 1939 infants 1939 infants
– Vaccinated at 2, 4, 6, and 15-16 months of ageVaccinated at 2, 4, 6, and 15-16 months of age
PENTACEL vaccine (n=484) vs Daptacel (3 lots), PENTACEL vaccine (n=484) vs Daptacel (3 lots), IPOL, ActHIB (n=1455)IPOL, ActHIB (n=1455)– All subjects received concomitant Recombivax HB All subjects received concomitant Recombivax HB
and Prevnarand Prevnar
ObjectiveObjective– Demonstrate non-inferiority of PENTACEL vs USDemonstrate non-inferiority of PENTACEL vs US
standard of care vaccines Daptacel, IPOL, ActHIBstandard of care vaccines Daptacel, IPOL, ActHIB
C-55
P3T06: PENTACEL vs US Standard of Care Vaccines Post-Dose 3: Pertussis GMTs
PENTACELPENTACEL Daptacel, IPOL, ActHIBDaptacel, IPOL, ActHIB
00
2020
4040
6060
8080
100100
GM
T (
EU
/mL
)G
MT
(E
U/m
L)
00
5050
100100
150150
200200
250250
300300
GM
T (
EU
/mL
)G
MT
(E
U/m
L)
PTPT FHAFHA PRNPRN FIMFIM
PENTACELPENTACEL 90.090.0 73.773.7 36.136.1 268.2268.2
ControlControl 63.863.8 29.229.2 43.343.3 267.2267.2
C-56
P3T06: PENTACEL vs US Standard of Care VaccinesPost-Dose 3: Pertussis 4-Fold Rise Rates
PENTACELPENTACEL 93.693.6 81.981.9 74.274.2 91.791.7
ControlControl 86.186.1 60.960.9 75.475.4 86.386.3
PENTACELPENTACEL Daptacel, IPOL, ActHIBDaptacel, IPOL, ActHIB
00
2020
4040
6060
8080
100100
PTPT FHAFHA PRNPRN FIMFIM
Per
cen
tP
erce
nt
C-57
P3T06: PENTACEL vs US Standard of Care VaccinesPost-Dose 3: Pertussis Non-Inferiority ComparisonsNon-Inferiority Comparisons
Non-inferiority is based on 90% confidence intervals.
C-58
P3T06: PENTACEL vs US Standard of Care Vaccines Post-Dose 4: Pertussis GMTs
PENTACELPENTACEL 174.0174.0 107.9107.9 93.693.6 553.4553.4
ControlControl 168.5168.5 64.064.0 186.1186.1 513.5513.5
PENTACELPENTACEL Daptacel and ActHIBDaptacel and ActHIB
00
4040
8080
120120
160160
200200
PTPT FHAFHA PRNPRN00
100100
200200
300300
400400
500500
600600
FIMFIM
GM
T (
EU
/mL
)G
MT
(E
U/m
L)
GM
T (
EU
/mL
)G
MT
(E
U/m
L)
C-59
P3T06: PENTACEL vs US Standard of Care VaccinesPost-Dose 4: Pertussis 4-Fold Rise Rates
PENTACELPENTACEL 97.497.4 88.488.4 92.792.7 93.593.5
ControlControl 97.197.1 79.379.3 98.398.3 91.691.6
PENTACELPENTACEL Daptacel and ActHIBDaptacel and ActHIB
00
2020
4040
6060
8080
100100
Per
cen
tP
erce
nt
PTPT FHAFHA PRNPRN FIMFIM
C-60
P3T06: PENTACEL vs US Standard of Care VaccinesPost-Dose 4: Pertussis Non-Inferiority ComparisonsNon-Inferiority Comparisons
Non-inferiority is based on 90% confidence intervals.
C-61
P3T06: PENTACEL vs US Standard of Care VaccinesPost-Dose 4: 4-Fold Rise Responses to Multiple Pertussis Antigens
PENTACELPENTACEL 0.90.9 99.199.1 98.298.2 94.394.3 79.879.8
ControlControl 0.40.4 99.699.6 98.798.7 94.894.8 73.373.3
PENTACELPENTACEL Daptacel and ActHIBDaptacel and ActHIB
NoneNone Any 1 of 4Any 1 of 4 Any 2 of 4Any 2 of 4 Any 3 of 4Any 3 of 4 All 4All 400
2020
4040
6060
8080
100100
Per
cen
tP
erce
nt
C-62
PENTACEL Bridge to EfficacyPENTACEL Bridge to EfficacyP3T06 vs Sweden I Efficacy TrialP3T06 vs Sweden I Efficacy Trial
NIH-sponsored efficacy trial in Sweden 1992-1995NIH-sponsored efficacy trial in Sweden 1992-1995– Infants received Daptacel at 2, 4, 6 months of ageInfants received Daptacel at 2, 4, 6 months of age
– 85% efficacy vs WHO-defined classic pertussis85% efficacy vs WHO-defined classic pertussis
– 78% efficacy vs any pertussis (lab-confirmed, 78% efficacy vs any pertussis (lab-confirmed, 1 day of cough)1 day of cough)
Pertussis antibody levels in Sweden I Efficacy Trial Pertussis antibody levels in Sweden I Efficacy Trial were compared to those following 4 doses of were compared to those following 4 doses of PENTACEL in US pivotal trials P3T06 and 494-01PENTACEL in US pivotal trials P3T06 and 494-01
Sera from P3T06, 494-01 and the Sweden I Efficacy Sera from P3T06, 494-01 and the Sweden I Efficacy Trial were tested contemporaneously in same Trial were tested contemporaneously in same laboratory, under same conditions, using the same laboratory, under same conditions, using the same validated assayvalidated assay
C-63
P3T06: PENTACEL vs Sweden I (Bridge to Efficacy) GMTs
PENTACELPENTACEL 174.0174.0 107.9107.9 93.693.6 553.4553.4
Sweden ISweden I 87.587.5 40.740.7 111.3111.3 339.3339.3
PENTACELPENTACEL Sweden ISweden I
00
4040
8080
120120
160160
200200
PTPT FHAFHA PRNPRN00
100100
200200
300300
400400
500500
600600
FIMFIM
GM
T (
EU
/mL
)G
MT
(E
U/m
L)
GM
T (
EU
/mL
)G
MT
(E
U/m
L)
C-64
P3T06: PENTACEL vs Sweden I (Bridge to Efficacy) Non-Inferiority Analyses
Non-inferiority is based on 90% confidence intervals for GMTs and VR; 95% for 4-fold rise.
C-65
494-01: Lot Consistency494-01: Lot ConsistencyPENTACEL vs ControlPENTACEL vs Control
Multi-center, randomized, controlled, open-label Multi-center, randomized, controlled, open-label lot-consistency studylot-consistency study– 3538 infants 3538 infants
– Vaccinated at 2, 4, 6, and 15 months of ageVaccinated at 2, 4, 6, and 15 months of age
PENTACEL (3 lots, n=2506) vs HCPDT, Poliovax, PENTACEL (3 lots, n=2506) vs HCPDT, Poliovax, ActHIB given separately (n=1032)ActHIB given separately (n=1032)– All subjects received concomitant Recombivax HBAll subjects received concomitant Recombivax HB
– Most subjects received concomitant PrevnarMost subjects received concomitant Prevnar
ObjectivesObjectives– Lot consistencyLot consistency
– Non-inferiorityNon-inferiority
C-66
494-01: Lot Consistency, 494-01: Lot Consistency, Post-Dose 3Post-Dose 3, , Pertussis Pertussis
Lot consistency is based on 90% confidence intervals.
C-67
494-01: PENTACEL vs HCPDT, Poliovax, ActHIB Post-Dose 3: Pertussis GMTs
PENTACELPENTACEL 99.799.7 76.276.2 39.639.6 270.3270.3
ControlControl 84.584.5 69.269.2 38.638.6 246.0246.0
00
2020
4040
6060
8080
100100
PTPT FHAFHA PRNPRN FIMFIM00
5050
100100
150150
200200
250250
300300
GM
T (
EU
/mL
)G
MT
(E
U/m
L)
PENTACELPENTACEL HCPDT, Poliovax, ActHIBHCPDT, Poliovax, ActHIB
GM
T (
EU
/mL
)G
MT
(E
U/m
L)
C-68
494-01: PENTACEL vs HCPDT, Poliovax, ActHIB Post-Dose 3: Pertussis 4-Fold Rise Rates
PENTACELPENTACEL 90.390.3 80.380.3 73.273.2 86.286.2
ControlControl 89.789.7 78.078.0 78.678.6 87.087.0
PENTACELPENTACEL HCPDT, Poliovax, ActHIBHCPDT, Poliovax, ActHIB
00
2020
4040
6060
8080
100100
Per
cen
tP
erce
nt
PTPT FHAFHA PRNPRN FIMFIM
C-69
494-01: PENTACEL vs HCPDT, Poliovax, ActHIB Post-Dose 3: Pertussis Non-Inferiority Analyses
Non-inferiority is based on 90% confidence intervals.
C-70
494-01: PENTACEL vs HCPDT, Poliovax, ActHIB Post-Dose 4: Pertussis GMTs
PENTACELPENTACEL 202.2202.2 134.6134.6 94.994.9 514.2514.2
ControlControl 188.6188.6 128.3128.3 129.9129.9 350.3350.3
PENTACELPENTACEL HCPDT, Poliovax, ActHIBHCPDT, Poliovax, ActHIB
00
2525
5050
7575
100100
125125
150150
175175
200200
225225
00
5050
100100
150150
200200
250250
300300
350350
400400
450450
500500
550550
GM
T (
EU
/mL
)G
MT
(E
U/m
L)
PTPT FHAFHA PRNPRN FIMFIM
GM
T (
EU
/mL
)G
MT
(E
U/m
L)
C-71
494-01: PENTACEL vs HCPDT, Poliovax, ActHIB Post-Dose 4: Pertussis 4-Fold Rise Rates
PENTACELPENTACEL 95.495.4 90.290.2 89.389.3 91.391.3
ControlControl 94.494.4 86.386.3 92.892.8 87.987.9
PENTACELPENTACEL HCPDT, Poliovax, ActHIBHCPDT, Poliovax, ActHIB
0
20
40
60
80
100
Per
cen
t
PT FHA PRN FIM
C-72
494-01: PENTACEL vs HCPDT, Poliovax, ActHIB Post-Dose 4: Pertussis Non-Inferiority Analyses
Non-inferiority is based on 90% confidence intervals.
C-73
494-01: PENTACEL vs Sweden I (Bridge to Efficacy) 494-01: PENTACEL vs Sweden I (Bridge to Efficacy) GMTsGMTs
PENTACELPENTACEL Sweden ISweden I
00
4040
8080
120120
160160
200200
00
100100
200200
300300
400400
500500
600600
GM
T (
EU
/mL
)G
MT
(E
U/m
L)
GM
T (
EU
/mL
)G
MT
(E
U/m
L)
PTPT FHAFHA PRNPRN FIMFIM
PENTACELPENTACEL 195.1195.1 129.9129.9 90.890.8 506.6506.6
Sweden ISweden I 87.587.5 40.740.7 111.3111.3 339.3339.3
C-74
494-01: PENTACEL vs Sweden I (Bridge to Efficacy) 4-Fold Rise Rates
PENTACELPENTACEL 94.994.9 91.791.7 89.289.2 91.591.5
Sweden ISweden I 86.386.3 68.868.8 98.898.8 86.386.3
PENTACELPENTACEL Sweden ISweden I
00
2020
4040
6060
8080
100100
Per
cen
tP
erce
nt
PTPT FHAFHA PRNPRN FIMFIM
C-75
494-01: PENTACEL vs Sweden I (Bridge to Efficacy) Non-Inferiority Analyses
Non-inferiority is based on 90% confidence intervals for GMTs and VR; 95% for 4-fold rise.
C-76
494-01: PENTACEL vs Sweden I (Bridge to Efficacy) Box Plot of 2-Month Baseline PRN Antibody LevelsBox Plot of 2-Month Baseline PRN Antibody Levels
Per
tact
in (
EU
/mL
)P
erta
ctin
(E
U/m
L)
494-01 Stage I (n=507) Sweden I (n=80)
0
20
40
80
60
100
120
140
160
180
200
12: 11% (65/507)12: 11% (65/507) 12: 1% (1/80)12: 1% (1/80)
C-77
PENTACEL PENTACEL Post-Dose 4Post-Dose 4 vs Sweden I vs Sweden I RCDCs: PTRCDCs: PT
PENTACEL, P3T06PENTACEL, M5A07PENTACEL, 494-01PENTACEL, 494-03PENTACEL, 5A9908Daptacel, SWEDEN I
C-78
PENTACEL PENTACEL Post-Dose 4Post-Dose 4 vs Sweden I vs Sweden I RCDCs: FHARCDCs: FHA
PENTACEL, P3T06PENTACEL, M5A07PENTACEL, 494-01PENTACEL, 494-03PENTACEL, 5A9908Daptacel, SWEDEN I
C-79
PENTACEL PENTACEL Post-Dose 4Post-Dose 4 vs Sweden I vs Sweden I RCDCs: PRNRCDCs: PRN
PENTACEL, P3T06PENTACEL, M5A07PENTACEL, 494-01PENTACEL, 494-03PENTACEL, 5A9908Daptacel, SWEDEN I
C-80
PENTACEL PENTACEL Post-Dose 4Post-Dose 4 vs Sweden I vs Sweden I RCDCs: FIMRCDCs: FIM
FIM Antibody (EU/mL)FIM Antibody (EU/mL)
PENTACEL, P3T06PENTACEL, M5A07PENTACEL, 494-01PENTACEL, 494-03PENTACEL, 5A9908Daptacel, SWEDEN I
C-81
55thth Dose Follow-up Studies to 494-01, P3T06: Dose Follow-up Studies to 494-01, P3T06: P3T10 and P3T11 (Studies Currently Underway)P3T10 and P3T11 (Studies Currently Underway)
Both studies were multi-center, randomized, Both studies were multi-center, randomized, open-labelopen-label
Solicited all PENTACEL or Daptacel recipients Solicited all PENTACEL or Daptacel recipients in P3T06 and 494-01 to participatein P3T06 and 494-01 to participate
Sample size for pertussis immunogenicitySample size for pertussis immunogenicity– 259 in P3T10259 in P3T10
– 363 in P3T11 (89 primed with PENTACEL, 363 in P3T11 (89 primed with PENTACEL, 274 primed with Daptacel)274 primed with Daptacel)
Blood obtained for serology immediately prior Blood obtained for serology immediately prior to 5to 5thth dose dose
C-82
Percent Seropositive* at Percent Seropositive* at Pre-Dose 5Pre-Dose 5, , By Study and Pertussis AntigenBy Study and Pertussis Antigen
**LOQ: PT, 5; FHA, 3; PRN, 3; FIM, 17 LOQ: PT, 5; FHA, 3; PRN, 3; FIM, 17
75.375.3
89.689.6 89.689.6
77.677.674.274.2 74.274.2
87.687.6
68.568.5
58.858.8 59.359.3
95.395.3
54.754.7
Per
cen
t P
erce
nt
LO
Q L
OQ
PENTACEL (P3T10)PENTACEL (P3T10) PENTACEL (P3T11)PENTACEL (P3T11) Daptacel (P3T11)Daptacel (P3T11)
00
2020
4040
6060
8080
100100
PTPT FHAFHA PRNPRN FIMFIM
C-83
Immunogenicity Presentation Sequence Immunogenicity Presentation Sequence
Pertussis ImmunogenicityPertussis Immunogenicity
Hib (PRP) ImmunogenicityHib (PRP) Immunogenicity
Diphtheria and Tetanus ImmunogenicityDiphtheria and Tetanus Immunogenicity
Polio ImmunogenicityPolio Immunogenicity
Co-Administration with Other Licensed VaccinesCo-Administration with Other Licensed Vaccines
C-84
P3T06: PENTACEL vs US Standard of Care VaccinesPost-Doses 3 and 4: Hib Seroprotection Rates
PENTACELPENTACEL Daptacel, IPOL, ActHIBDaptacel, IPOL, ActHIB
PENTACELPENTACEL 92.392.3 72.172.1 97.897.8
ControlControl 93.393.3 70.870.8 95.995.9
Per
cen
tP
erce
nt
Post-Dose 4Post-Dose 4Post-Dose 3Post-Dose 3
00
2020
4040
6060
8080
100100
0.15 0.15 µg/mLµg/mL 1.0 1.0 µg/mLµg/mL 1.0 1.0 µg/mLµg/mL
C-85
P3T06: PENTACEL vs US Standard of Care VaccinesPost-Doses 3 and 4: Hib GMTs
PENTACELPENTACEL Daptacel, IPOL, ActHIBDaptacel, IPOL, ActHIB
PENTACELPENTACEL 2.312.31 17.7117.71
ControlControl 2.292.29 20.4920.49
GM
T (
µg
/mL
)G
MT
(µ
g/m
L)
Post-Dose 3Post-Dose 3 Post-Dose 4Post-Dose 400
11
22
33
00
55
1010
1515
2020
2525
GM
T (
µg
/mL
)G
MT
(µ
g/m
L)
C-86
P3T06: Non-inferiority Testing of Hib Seroprotection Rates P3T06: Non-inferiority Testing of Hib Seroprotection Rates (Control-PENTACEL) and GMT Ratios (Control/PENTACEL)(Control-PENTACEL) and GMT Ratios (Control/PENTACEL)
% % 0.15 0.15 µg/mLµg/mL
% % 1.0 1.0 µg/mLµg/mL
% % 1.0 1.0 µg/mLµg/mL
C-87
% 1.0 µg/mL
% 0.15 µg/mL
494-01: Lot Consistency, 494-01: Lot Consistency, Post-Dose 3Post-Dose 3: Hib: Hib
Lot consistency is based on 90% confidence intervals.
C-88
494-01: GMTs and Seroprotection Rates, PENTACEL Lots at Post-Dose 3: Hib
Lot 1Lot 1 Lot 2Lot 2 Lot 3Lot 3
00
0.50.5
1.01.0
1.51.5
2.02.0
2.52.5
3.03.0
3.53.5
4.04.0
GM
T (
GM
T (
µµg
/mL
)g
/mL
)
00
2020
4040
6060
8080
100100
Per
cen
tP
erce
nt
94.594.5
78.578.5
95.095.0
77.277.2
96.796.7
81.781.7
0.15 0.15 µµg/mLg/mL 1.0 1.0 µµg/mLg/mL
3.13.12.92.9
3.63.6
C-89
494-01: PENTACEL vs HCPDT, Poliovax, ActHIB Post-Doses 3 and 4: Hib Seroprotection Rates
PENTACELPENTACEL 95.495.4 79.179.1 98.298.2
ControlControl 98.398.3 88.888.8 99.099.0
PENTACELPENTACEL HCPDT, Poliovax, ActHIBHCPDT, Poliovax, ActHIB
00
2020
4040
6060
8080
100100
Per
cen
tP
erce
nt
0.15 0.15 µg/mLµg/mL 1.0 1.0 µg/mLµg/mL
Post-Dose 3Post-Dose 3 Post-Dose 4Post-Dose 4
1.0 1.0 µg/mLµg/mL
C-90
P3T06 and 494-01: Comparison of Hib GMTs P3T06 and 494-01: Comparison of Hib GMTs Post-Doses 3 and 4Post-Doses 3 and 4
PENTACELPENTACEL 3.193.19
ControlControl 6.236.23
PENTACELPENTACEL ControlControl
0
1
2
3
4
5
6
7
494-01
Post-Dose 3
0
5
10
15
20
25
30
35
40
494-01
Post-Dose 4
24.1224.12
35.9035.90
GM
T (
GM
T (
µµg
/mL
)g
/mL
)
GM
T (
GM
T (
µµg
/mL
)g
/mL
)
C-91
P3T06 and 494-01: Comparison of Hib GMTs P3T06 and 494-01: Comparison of Hib GMTs Post-Doses 3 and 4Post-Doses 3 and 4
PENTACELPENTACEL 2.312.31 3.193.19
ControlControl 2.292.29 6.236.23
PENTACELPENTACEL ControlControl
00
11
22
33
44
55
66
77
P3T06P3T06 494-01494-01
GM
T (
GM
T (
µµg
/mL
)g
/mL
)
P3T06P3T06 494-01494-01
17.7117.71 24.1224.12
20.4920.49 35.9035.90
GM
T (
GM
T (
µµg
/mL
)g
/mL
)
Post-Dose 3Post-Dose 3 Post-Dose 4Post-Dose 4
00
55
1010
1515
2020
2525
3030
3535
4040
C-92
494-01: Non-inferiority Testing of Hib Seroprotection Rates 494-01: Non-inferiority Testing of Hib Seroprotection Rates (Control-PENTACEL) and GMT Ratios (Control/PENTACEL)(Control-PENTACEL) and GMT Ratios (Control/PENTACEL)
Non-inferiority is based on 90% confidence intervals.
% % 0.15 0.15 µg/mLµg/mL
% % 1.0 1.0 µg/mLµg/mL
% % 1.0 1.0 µg/mLµg/mL
C-93
P3T06 and 494-01: Comparison of Hib GMTs P3T06 and 494-01: Comparison of Hib GMTs Post-Doses 3 and 4Post-Doses 3 and 4
PENTACELPENTACEL 2.312.31 3.193.19
ControlControl 2.292.29 6.236.23
PENTACELPENTACEL ControlControl
00
11
22
33
44
55
66
77
P3T06P3T06 494-01494-01
GM
T (
GM
T (
µµg
/mL
)g
/mL
)
P3T06P3T06 494-01494-01
17.7117.71 24.1224.12
20.4920.49 35.9035.90
GM
T (
GM
T (
µµg
/mL
)g
/mL
)
Post-Dose 3Post-Dose 3 Post-Dose 4Post-Dose 4
00
55
1010
1515
2020
2525
3030
3535
4040
C-94
US and Canadian PENTACEL Licensure Trials: US and Canadian PENTACEL Licensure Trials: Post-Dose 3: Post-Dose 3: Hib GMTs by TrialHib GMTs by Trial
PENTACEL Studies: 494-01, P3T06, M5A07, 494-03, M5A03, PB9502, PB9601PENTACEL Studies: 494-01, P3T06, M5A07, 494-03, M5A03, PB9502, PB9601ActHIB Studies: P3T07, 494-01, P3T06, PB9502ActHIB Studies: P3T07, 494-01, P3T06, PB9502
00
11
22
33
44
55
66
77
88
PENTACELPENTACEL ActHIBActHIB
GM
T (
GM
T (
µµg
/mL
)g
/mL
)
494-01494-01
C-95
PENTACEL Studies: 494-01, P3T06, 5A9908, 494-03, M5A03, PB9502, PB9601PENTACEL Studies: 494-01, P3T06, 5A9908, 494-03, M5A03, PB9502, PB9601ActHIB Studies: 494-01, P3T06, PB9502ActHIB Studies: 494-01, P3T06, PB9502
US and Canadian PENTACEL Licensure Trials: US and Canadian PENTACEL Licensure Trials: Post-Dose 4: Post-Dose 4: Hib GMTs by TrialHib GMTs by Trial
494-01494-01
00
55
1010
1515
2020
2525
3030
3535
4040
4545
GM
T (
GM
T (
µµg
/mL
)g
/mL
)
PENTACELPENTACEL ActHIBActHIB
C-96
P3T06: Hib GMTs by Study Site P3T06: Hib GMTs by Study Site ((10 Subjects), 10 Subjects), Post-Dose 3Post-Dose 3
00
11
22
33
44
55
66
77
PENTACELPENTACEL ActHIBActHIB
GM
T (
GM
T (
µµg
/mL
)g
/mL
)
C-97
P3T06: Hib GMTs by Study Site P3T06: Hib GMTs by Study Site Post-Dose 3:Post-Dose 3: PENTACEL vs Control by Site PENTACEL vs Control by Site
Shows only sites with Shows only sites with 10 PENTACEL subjects per group10 PENTACEL subjects per group
00
11
22
33
44
55
66
77
PENTACELPENTACEL ActHIBActHIB
GM
T (
GM
T (
µµg
/mL
)g
/mL
)
C-98
Hib GMTs at Hib GMTs at Post-Dose 3Post-Dose 3, By Study, By StudyPENTACELPENTACEL ActHIB Given SeparatelyActHIB Given Separately
4.44.4
7.17.1
3.23.22.82.8
2.32.3
3.03.03.53.5
3.83.8
6.26.2
2.32.3
3.03.0
00
11
22
33
44
55
66
77
88
PENTACELPENTACEL ControlControl
GM
T (
GM
T (
µµg
/mL
)g
/mL
)
PB9502PB9502 PB9601PB9601 494-01494-01 494-03494-03 P3T06P3T06 M5A03M5A03 M5A07M5A07 494-01494-01 P3T06P3T06 P3T07P3T07PB9502PB9502
C-99
Hib GMTs at Hib GMTs at Pre-Dose 4Pre-Dose 4, By Study, By Study
0.420.42
0.600.60
0.380.38
0.310.31
0.560.56
0.290.29 0.300.300.370.37
0.560.56
0.250.250.250.25
0.500.50
0.750.75
1.001.00
GM
T (
GM
T (
µµg
/mL
)g
/mL
)
ControlControl
PENTACELPENTACEL ActHIB Given SeparatelyActHIB Given Separately
0.320.32
PB9502PB9502 PB9601PB9601 5A99085A9908 494-01494-01 494-03494-03 P3T06P3T06 M5A03M5A03 PB9502PB9502 494-01494-01 P3T06P3T06M5A07M5A07
PENTACELPENTACEL
00
C-100
Hib GMTs at Hib GMTs at Post-Dose 4Post-Dose 4, By Study, By StudyPENTACELPENTACEL ActHIB Given SeparatelyActHIB Given Separately
1010
2020
3030
4040
30.130.1
PB9502PB9502
39.839.8
PB9601PB9601
32.532.5
5A99085A9908
24.124.1
494-01494-01
36.736.7
494-03494-03
17.717.7
P3T06P3T06
25.625.6
M5A03M5A03
27.127.1
PB9502PB9502
35.935.9
494-01494-01
20.520.5
P3T06P3T06
GM
T (
GM
T (
µµg
/mL
)g
/mL
)
24.124.1
M5A07M5A07
ControlControlPENTACELPENTACEL
00
C-101
Hib GMTs at Pre-Dose 5, By Study
2.062.06
1.481.481.391.39
GM
T (
GM
T (
μμg
/mL
)g
/mL
)
00
0.50.5
1.01.0
1.51.5
2.02.0
2.52.52.522.52
PENTACELPENTACEL Separate VaccinesSeparate Vaccines
ActHIBActHIBTD508TD508P3T10P3T10 P3T11P3T11
PENTACELPENTACEL ControlControl
C-102
Hib Seroprotection (Hib Seroprotection (1.0 1.0 µg/mLµg/mL) ) at at Post-Dose 3Post-Dose 3, By Study, By Study
PENTACELPENTACEL ActHIB Given SeparatelyActHIB Given Separately
84.784.7
95.595.5
79.179.175.675.6
72.172.178.578.5 78.478.4
88.988.9 88.888.8
70.870.875.775.7
Per
cen
tP
erce
nt
00
2020
4040
6060
8080
100100
PB9502PB9502 PB9601PB9601 494-01494-01 494-03494-03 P3T06P3T06 M5A03M5A03 M5A07M5A07 494-01494-01 P3T06P3T06 P3T07P3T07PB9502PB9502
PENTACELPENTACEL ControlControl
C-103
Hib Seroprotection (Hib Seroprotection (0.15 0.15 µg/mLµg/mL) ) at at Pre-Dose 4Pre-Dose 4, By Study, By Study
PENTACELPENTACEL ActHIB Given SeparatelyActHIB Given Separately
75.475.4
84.884.8
73.073.068.668.6
83.883.8
65.465.4 67.767.773.173.1
80.880.8
60.760.7
69.169.1
PB9502PB9502 PB9601PB9601 5A99085A9908 494-01494-01 494-03494-03 P3T06P3T06 M5A03M5A03 PB9502PB9502 494-01494-01 P3T06P3T06M5A07M5A07
Per
cen
tP
erce
nt
00
2020
4040
6060
8080
100100
ControlControlPENTACELPENTACEL
C-104
Hib Seroprotection (Hib Seroprotection (1.0 1.0 µg/mLµg/mL) ) at at Post-Dose 4Post-Dose 4, By Study, By Study
PENTACELPENTACEL ActHIB Given SeparatelyActHIB Given Separately
99.099.0 100.0100.0 98.898.8 98.298.2 99.199.1 97.897.8 97.397.3 100.0100.0 99.099.095.995.997.997.9
Per
cen
tP
erce
nt
00
2020
4040
6060
8080
100100
PB9502PB9502 PB9601PB9601 5A99085A9908 494-01494-01 494-03494-03 P3T06P3T06 M5A03M5A03 PB9502PB9502 494-01494-01 P3T06P3T06M5A07M5A07
ControlControlPENTACELPENTACEL
C-105
Hib Seroprotection (≥0.15 Hib Seroprotection (≥0.15 µg/mLµg/mL) at ) at Pre-Dose 5Pre-Dose 5, By Study, By Study
PENTACELPENTACEL ActHIB Given SeparatelyActHIB Given Separately
96.596.591.791.7 94.394.3
P3T11P3T1100
2020
4040
6060
8080
10010098.498.4
TD508TD508P3T10P3T10 P3T11P3T11
PENTACELPENTACEL ControlControl
Per
cen
tP
erce
nt
C-106
P3T07: Daptacel+IPOL+ActHIB - No Concomitant Prevnar M5A07: PENTACEL - No Concomitant Prevnar Post-Dose 3: Hib Seroprotection Rates and GMTs
≥≥0.15 0.15 μμg/mLg/mL ≥≥1.0 1.0 μμg/mLg/mL
PENTACELPENTACEL 95.395.3 79.679.6 3.63.6
Daptacel, IPOL, ActHIBDaptacel, IPOL, ActHIB 93.593.5 73.273.2 2.72.7
PENTACELPENTACEL Daptacel, IPOL, ActHIBDaptacel, IPOL, ActHIB
00
11
22
33
44
55
00
2020
6060
8080
100100
4040Per
cen
tP
erce
nt
GM
T (
GM
T (
μμg
/mL
)g
/mL
)
C-107
P3T07: Daptacel+IPOL+ActHIB - with Concomitant Prevnar M5A07: PENTACEL - with Concomitant Prevnar Post-Dose 3: Hib Seroprotection Rates and GMTs
PENTACEL, PrevnarPENTACEL, Prevnar 95.895.8 77.177.1 3.33.3
Daptacel, IPOL, ActHIB, PrevnarDaptacel, IPOL, ActHIB, Prevnar 94.494.4 80.380.3 3.83.8
PENTACEL, PrevnarPENTACEL, Prevnar Daptacel, IPOL, ActHIB, PrevnarDaptacel, IPOL, ActHIB, Prevnar
00
11
22
33
44
55
00
2020
6060
8080
100100
4040Per
cen
tP
erce
nt
≥≥0.15 0.15 μμg/mLg/mL ≥≥1.0 1.0 μμg/mLg/mL
GM
T (
GM
T (
μμg
/mL
)g
/mL
)
C-108
PENTACEL vs Standard of CarePENTACEL vs Standard of CarePost-Dose 3:Post-Dose 3: Hib RCDCs Hib RCDCs
Hib Antibody (Hib Antibody (µg/mL)µg/mL)
C-109
Immunogenicity Presentation Sequence Immunogenicity Presentation Sequence
Pertussis ImmunogenicityPertussis Immunogenicity
Hib (PRP) ImmunogenicityHib (PRP) Immunogenicity
Diphtheria and Tetanus ImmunogenicityDiphtheria and Tetanus Immunogenicity
Polio ImmunogenicityPolio Immunogenicity
Co-Administration with Other Licensed VaccinesCo-Administration with Other Licensed Vaccines
C-110
P3T06: PENTACEL vs US Standard of Care Vaccines Post-Dose 3: Diphtheria, Tetanus Seroprotection Rates
PENTACELPENTACEL 100.0100.0 98.898.8 100.0100.0 99.799.7
ControlControl 100.0100.0 98.598.5 100.0100.0 100.0100.0
PENTACELPENTACEL Daptacel, IPOL, ActHIBDaptacel, IPOL, ActHIB
0.01 IU/mL0.01 IU/mL 0.1 IU/mL0.1 IU/mL
DiphtheriaDiphtheria TetanusTetanus0.01 IU/mL0.01 IU/mL 0.1 IU/mL0.1 IU/mL
00
2020
4040
6060
8080
100100
Per
cen
tP
erce
nt
C-111
P3T06: PENTACEL vs US Standard of Care Vaccines Post-Dose 4: Diphtheria, Tetanus Seroprotection Rates
PENTACELPENTACEL 100.0100.0 96.596.5 100.0100.0 92.992.9
ControlControl 100.0100.0 95.795.7 100.0100.0 99.499.4
PENTACELPENTACEL Daptacel and ActHIBDaptacel and ActHIB
0.1 IU/mL0.1 IU/mL 1.0 IU/mL1.0 IU/mL
DiphtheriaDiphtheria TetanusTetanus0.1 IU/mL0.1 IU/mL 1.0 IU/mL1.0 IU/mL
00
2020
4040
6060
8080
100100
Per
cen
tP
erce
nt
C-112
494-01: PENTACEL vs HCPDT, Poliovax, ActHIB494-01: PENTACEL vs HCPDT, Poliovax, ActHIBPost-Dose 3Post-Dose 3: Diphtheria, Tetanus Seroprotection Rates: Diphtheria, Tetanus Seroprotection Rates
PENTACELPENTACEL 99.899.8 92.192.1 100.0100.0 99.999.9
ControlControl 99.799.7 92.292.2 100.0100.0 100.0100.0
PENTACELPENTACEL HCPDT, Poliovax, ActHIBHCPDT, Poliovax, ActHIB
0.01 IU/mL0.01 IU/mL 0.1 IU/mL0.1 IU/mL
DiphtheriaDiphtheria TetanusTetanus0.01 IU/mL0.01 IU/mL 0.1 IU/mL0.1 IU/mL
00
2020
4040
6060
8080
100100
Per
cen
tP
erce
nt
C-113
494-01: PENTACEL vs HCPDT, Poliovax, ActHIB 494-01: PENTACEL vs HCPDT, Poliovax, ActHIB Post-Dose 4Post-Dose 4: Diphtheria, Tetanus Seroprotection Rates: Diphtheria, Tetanus Seroprotection Rates
PENTACELPENTACEL 100.0100.0 95.595.5 100.0100.0 93.493.4
ControlControl 99.799.7 95.195.1 100.0100.0 98.698.6
PENTACELPENTACEL HCPDT, Poliovax, ActHIBHCPDT, Poliovax, ActHIB
00
2020
4040
6060
8080
100100
Per
cen
tP
erce
nt
0.1 IU/mL0.1 IU/mL 1.0 IU/mL1.0 IU/mL
DiphtheriaDiphtheria TetanusTetanus0.1 IU/mL0.1 IU/mL 1.0 IU/mL1.0 IU/mL
C-114
PENTACEL Non-inferiority, P3T06 and 494-01:PENTACEL Non-inferiority, P3T06 and 494-01:Diphtheria and Tetanus Seroprotection RatesDiphtheria and Tetanus Seroprotection Rates
Non-inferiority is based on 90% confidence intervals.
% % 0.1 0.1 IU/mLIU/mL% % 0.01 0.01 IU/mLIU/mL
% % 0.1 0.1 IU/mLIU/mL% % 0.01 0.01 IU/mLIU/mL
% % 0.1 0.1 IU/mLIU/mL% % 0.01 0.01 IU/mLIU/mL
% % 0.1 0.1 IU/mLIU/mL% % 0.01 0.01 IU/mLIU/mL
% % 0.1 0.1 IU/mLIU/mL% % 0.01 0.01 IU/mLIU/mL
% % 0.1 0.1 IU/mLIU/mL% % 0.01 0.01 IU/mLIU/mL
% % 0.1 0.1 IU/mLIU/mL% % 0.01 0.01 IU/mLIU/mL
% % 0.1 0.1 IU/mLIU/mL% % 0.01 0.01 IU/mLIU/mL
C-115
Immunogenicity Presentation Sequence Immunogenicity Presentation Sequence
Pertussis ImmunogenicityPertussis Immunogenicity
Hib (PRP) ImmunogenicityHib (PRP) Immunogenicity
Diphtheria and Tetanus ImmunogenicityDiphtheria and Tetanus Immunogenicity
Polio ImmunogenicityPolio Immunogenicity
Co-Administration with Other Licensed VaccinesCo-Administration with Other Licensed Vaccines
C-116
P3T06 and 494-01: PENTACEL vs ControlPolio Seroprotection Rates (1:8)
PENTACELPENTACEL 99.499.4 100.0100.0 100.0100.0 99.799.7 100.0100.0 100.0100.0 100.0100.0 100.0100.0 100.0100.0
ControlControl 100.0100.0 100.0100.0 100.0100.0 100.0100.0 100.0100.0 100.0100.0 100.0100.0 100.0100.0 100.0100.0
Polio 1Polio 1 Polio 2Polio 2 Polio 3Polio 300
2020
4040
6060
8080
100100
Per
cen
tP
erce
nt
PENTACELPENTACEL Daptacel, IPOL and ActHIBDaptacel, IPOL and ActHIB HCPDT, Poliovax, ActHIBHCPDT, Poliovax, ActHIB
Polio 1Polio 1 Polio 2Polio 2 Polio 3Polio 3 Polio 1Polio 1 Polio 2Polio 2 Polio 3Polio 3
494-01 Post-Dose 3494-01 Post-Dose 3 494-01 Post-Dose 4494-01 Post-Dose 4P3T06 Post-Dose 3P3T06 Post-Dose 3
C-117
Polio 1 % 1:8
Polio 2 % 1:8
Polio 3 % 1:8
Polio 1 % 1:8
Polio 2 % 1:8
Polio 3 % 1:8
Polio 1 % 1:8
Polio 2 % 1:8
Polio 3 % 1:8
PENTACEL Non-inferiority, P3T06 and 494-01:PENTACEL Non-inferiority, P3T06 and 494-01:Polio Seroprotection RatesPolio Seroprotection Rates
Non-inferiority is based on 90% confidence intervals.
C-118
Immunogenicity Presentation Sequence Immunogenicity Presentation Sequence
Pertussis ImmunogenicityPertussis Immunogenicity
Hib (PRP) ImmunogenicityHib (PRP) Immunogenicity
Diphtheria and Tetanus ImmunogenicityDiphtheria and Tetanus Immunogenicity
Polio ImmunogenicityPolio Immunogenicity
Co-Administration with Other Licensed VaccinesCo-Administration with Other Licensed Vaccines
C-119
P3T06: PENTACEL vs US Standard of Care Vaccines Post-Dose 3: Pneumococcal Seroprotection Rates
PENTACELPENTACEL 100.0100.0 98.198.1 92.592.5 81.081.0 99.799.7 94.494.4 100.0100.0 96.396.3 100.0100.0 98.198.1 97.597.5 94.794.7 98.198.1 92.892.8
ControlControl 100.0100.0 98.998.9 91.491.4 80.780.7 99.399.3 96.796.7 99.399.3 97.497.4 99.599.5 97.897.8 97.997.9 95.695.6 96.996.9 91.391.3
PENTACELPENTACEL Daptacel, IPOL and ActHIBDaptacel, IPOL and ActHIB
00
2020
4040
6060
8080
100100
0.150.15 0.500.50
44 6B6B 9V9V 1414 18C18C 19F19F 23F23F
Per
cen
tP
erce
nt
0.150.15 0.500.50 0.150.15 0.500.50 0.150.15 0.500.50 0.150.15 0.500.50 0.150.15 0.500.50 0.150.15 0.500.50
C-120
494-03: Co-Administration With Other 494-03: Co-Administration With Other Recommended VaccinesRecommended Vaccines
Multi-center, randomized, open-label studyMulti-center, randomized, open-label study– PENTACEL 4PENTACEL 4thth dose dose†† given at 15 to 16 months of age given at 15 to 16 months of age
concomitantly with, or separately from, MMR, concomitantly with, or separately from, MMR, Varivax, and PrevnarVarivax, and Prevnar
– Only 4Only 4thth dose data are presented (n=958) dose data are presented (n=958)
Objective: Objective: – Determine the effect of PENTACEL on Determine the effect of PENTACEL on
co-administered vaccinesco-administered vaccines
††PENTACEL was previously administered at 2, 4, and 6 months of agePENTACEL was previously administered at 2, 4, and 6 months of age
C-121
494-03: Effect of PENTACEL on Concomitant VaccinesPrevnar 4th Dose
PENTACEL+PrevnarPENTACEL+Prevnar 100.0100.0 98.798.7 97.497.4 95.595.5 100.0100.0 98.798.7 100.0100.0 99.499.4 100.0100.0 98.798.7 100.0100.0 97.497.4 98.798.7 95.595.5
MMR+Varivax+PrevnarMMR+Varivax+Prevnar 100.0100.0 99.499.4 99.499.4 97.597.5 100.0100.0 99.499.4 100.0100.0 100.0100.0 99.499.4 98.798.7 99.499.4 96.296.2 98.798.7 95.695.6
PENTACEL+PrevnarPENTACEL+Prevnar MMR+Varivax+PrevnarMMR+Varivax+Prevnar
00
2020
4040
6060
8080
100100
0.150.15 0.500.50
44 6B6B 9V9V 1414 18C18C 19F19F 23F23F
Per
cen
tP
erce
nt
0.150.15 0.500.50 0.150.15 0.500.50 0.150.15 0.500.50 0.150.15 0.500.50 0.150.15 0.500.50 0.150.15 0.500.50
C-122
00
2525
5050
7575
100100
125125
150150
00
5050
100100
150150
200200
250250
300300
PTPT FHAFHA PRNPRN FIMFIM
GM
T (
EU
/mL
)G
MT
(E
U/m
L)
GM
T (
EU
/mL
)G
MT
(E
U/m
L)
M5A07: PENTACEL+Prevnar vs PENTACELPost-Dose 3: Pertussis GMTs
PENTACEL+PrevnarPENTACEL+Prevnar 103.6103.6 82.482.4 45.745.7 272.5272.5
PENTACELPENTACEL 102.8102.8 77.877.8 44.344.3 281.0281.0
PENTACELPENTACELPENTACEL+PrevnarPENTACEL+Prevnar
C-123
M5A07: PENTACEL+Prevnar vs PENTACELM5A07: PENTACEL+Prevnar vs PENTACELPost-Dose 4Post-Dose 4 Pertussis GMTs Pertussis GMTs
00
4040
8080
120120
160160
200200
00
100100
200200
300300
400400
500500
GM
T (
EU
/mL
)G
MT
(E
U/m
L)
GM
T (
EU
/mL
)G
MT
(E
U/m
L)
PTPT FHAFHA PRNPRN FIMFIM
PENTACEL+PrevnarPENTACEL+Prevnar 189.7189.7 116.2116.2 98.298.2 456.3456.3
PENTACELPENTACEL 189.3189.3 107.6107.6 93.393.3 486.9486.9
PENTACELPENTACELPENTACEL+PrevnarPENTACEL+Prevnar
C-124
M5A07: PENTACEL+Prevnar vs PENTACELPost-Dose 3: Hib Seroprotection Rates and GMTs
PENTACEL+PrevnarPENTACEL+Prevnar 95.895.8 77.177.1
PENTACELPENTACEL 95.395.3 79.679.6
3.323.32
3.603.60
00
2020
4040
6060
8080
100100
0.15 0.15 µµg/mL g/mL 1.0 1.0 µµg/mLg/mL
Per
cen
tP
erce
nt
GM
T (
µg
/mL
)G
MT
(µ
g/m
L)
00
11
22
33
44
55
66
PENTACELPENTACELPENTACEL+PrevnarPENTACEL+Prevnar
C-125
M5A07: PENTACEL+Prevnar vs PENTACEL Post-Dose 4: Hib Seroprotection Rates and GMTs
1.0 1.0 µµg/mLg/mL
PENTACELPENTACELPENTACEL+PrevnarPENTACEL+Prevnar
PENTACEL+PrevnarPENTACEL+Prevnar 97.797.7
PENTACELPENTACEL 98.298.2
00
2020
4040
6060
8080
100100
Per
cen
tP
erce
nt
00
55
1010
1515
2020
2525
3030
21.721.7
26.726.7
GM
T (
µg
/mL
)G
MT
(µ
g/m
L)
C-126
Overall Immunogenicity ConclusionsOverall Immunogenicity Conclusions
PENTACEL efficacy against Pertussis can be concluded PENTACEL efficacy against Pertussis can be concluded based on favorable serological comparison to the based on favorable serological comparison to the Sweden I Efficacy Trial Sweden I Efficacy Trial
PENTACEL produced Pertussis GMTs and PENTACEL produced Pertussis GMTs and seroresponse rates comparable to those seen with seroresponse rates comparable to those seen with separately administered vaccines separately administered vaccines
Good similarity of responses demonstrated across all Good similarity of responses demonstrated across all the US licensure trials (RCDCs)the US licensure trials (RCDCs)
Good antibody persistence up to 4-6 years of ageGood antibody persistence up to 4-6 years of age
PENTACEL produced Diphtheria, Tetanus, and PENTACEL produced Diphtheria, Tetanus, and Poliovirus seroprotection rates comparable to those Poliovirus seroprotection rates comparable to those seen with separately administered vaccinesseen with separately administered vaccines
C-127
Overall Immunogenicity ConclusionsOverall Immunogenicity Conclusions
PENTACEL produced Hib GMTs and seroprotection PENTACEL produced Hib GMTs and seroprotection rates that were:rates that were:– Comparable to separately administered US standard of Comparable to separately administered US standard of
care vaccinescare vaccines
– Similar across the full range of PENTACEL studiesSimilar across the full range of PENTACEL studies
– Very high following the 4Very high following the 4thth dose dose
– Persisted into the pre-school booster age Persisted into the pre-school booster age
PENTACEL can be co-administered with other routinely PENTACEL can be co-administered with other routinely recommended infant and toddler vaccinesrecommended infant and toddler vaccines
With respect to immune responses, PENTACEL is a With respect to immune responses, PENTACEL is a suitable replacement for separately administered suitable replacement for separately administered Daptacel, IPOL, and ActHIBDaptacel, IPOL, and ActHIB
C-128
PENTACEL - AgendaPENTACEL - Agenda
IntroductionIntroduction Luc Kuykens, MD, MPHLuc Kuykens, MD, MPHVP Regulatory AffairsVP Regulatory Affairs
SafetySafety Luc Kuykens, MD, MPHLuc Kuykens, MD, MPHVP Regulatory AffairsVP Regulatory Affairs
Immunogenicity Immunogenicity Michael Decker, MD, MPH Michael Decker, MD, MPH VP Scientific and Medical AffairsVP Scientific and Medical Affairs
Canadian Post-Marketing Canadian Post-Marketing EffectivenessEffectiveness
Scott Halperin, MDScott Halperin, MDProfessor of Pediatrics Professor of Pediatrics Dalhousie University, Halifax, CanadaDalhousie University, Halifax, Canada
US PerspectiveUS Perspective David Greenberg, MDDavid Greenberg, MDDirector Scientific and Medical AffairsDirector Scientific and Medical Affairs
ConclusionConclusion Luc Kuykens, MD, MPHLuc Kuykens, MD, MPHVP Regulatory AffairsVP Regulatory Affairs
C-129
Canadian Post-Marketing ExperienceCanadian Post-Marketing Experience
Licensed May 1997Licensed May 1997
Introduced nationally 1997-1998Introduced nationally 1997-1998
Universal and exclusive useUniversal and exclusive use
As of April 2006, more than 12 million dosesAs of April 2006, more than 12 million doses
Canadian schedule: 2, 4, 6, and 18 monthsCanadian schedule: 2, 4, 6, and 18 months
Quadracel (DTaP-IPV; PENTACEL without Hib) Quadracel (DTaP-IPV; PENTACEL without Hib) at 4-6 yearsat 4-6 years
C-130
Pertussis Incidence Rates, Canada, Pertussis Incidence Rates, Canada, 1924 – 20001924 – 2000
Source: Canadian Immunization Guide, 6Source: Canadian Immunization Guide, 6 thth ed., 2005:169. ed., 2005:169.
C-131
Age-specific Rates of Pertussis, Canada, Age-specific Rates of Pertussis, Canada, 1988 – 20051988 – 2005††
††Provisional data for 2003-2005.Provisional data for 2003-2005.Source: http://dsol-smed.hc-sc.gc.ca/dsol-smed/ndis/c_time_e.html and Notifiable Diseases Reporting System, Source: http://dsol-smed.hc-sc.gc.ca/dsol-smed/ndis/c_time_e.html and Notifiable Diseases Reporting System, Public Health Agency of CanadaPublic Health Agency of Canada
Year
0
50
100
150
200
250
300
Rat
e p
er 1
00,0
00R
ate
per
100
,000
88 90 92 94 96 98 00 02 04†
PENTACEL Introduced
<1 yr 1-4 yr 5-9 yr
C-132
Canadian IMPACT Surveillance NetworkCanadian IMPACT Surveillance Network
12 pediatric hospitals throughout Canada12 pediatric hospitals throughout Canada
90% of tertiary care pediatric beds 90% of tertiary care pediatric beds
Referrals from all provinces and territoriesReferrals from all provinces and territories
Children from birth through 16 years of ageChildren from birth through 16 years of age
Surveillance conducted by nurse monitor at Surveillance conducted by nurse monitor at each siteeach site
C-133
Annual Number of Hospitalized Cases of Annual Number of Hospitalized Cases of Pertussis, IMPACT Centers, 1993 – 2005Pertussis, IMPACT Centers, 1993 – 2005
Source: Bettinger et al., 6th Canadian Immunization Conference, Montreal, Quebec, Dec 5-8, 2004.Source: Bettinger et al., 6th Canadian Immunization Conference, Montreal, Quebec, Dec 5-8, 2004.Bettinger et al., Pediatr Infect Dis J. 2007;26:31-5.Bettinger et al., Pediatr Infect Dis J. 2007;26:31-5.
PENTACEL EraPENTACEL IntroductionWhole Cell Era
PENTACELUsed Nationally
0
50
100
150
200
250
300
350
93 94 95 96 97 98 99 00 01 02 03 04 05
Year
Nu
mb
er o
f C
ases
C-134
Number of Pertussis Cases by Age Group, Number of Pertussis Cases by Age Group, Northwest TerritoriesNorthwest Territories
Age (years)
Nu
mb
er o
f C
ases
1010
2020
3030
4040
5050
< 1 1-4 5-9
1993-1996Whole Cell
1997-2000PENTACEL
2001-2004PENTACEL
0
Source: Kandola K, et al. Source: Kandola K, et al. Can J Infect Dis Med Microbiol.Can J Infect Dis Med Microbiol. 2005;16:271-4. 2005;16:271-4.
C-135
Incidence of Invasive Hi* Disease in Children Incidence of Invasive Hi* Disease in Children Aged <5 Years, Canada, 1989 – 2005Aged <5 Years, Canada, 1989 – 2005
Data for 2003-2005 are provisional.Data for 2003-2005 are provisional.Source: Public Health Agency of Canada, 2006.Source: Public Health Agency of Canada, 2006.*Not all *Not all Haemophilus influenzaeHaemophilus influenzae were confirmed as type b. were confirmed as type b.
Year
PENTACEL Introduced
0
4
8
12
16
20
24
89 90 91 92 93 94 95 96 97 98 99 00 01 02 03 04 05
Rat
e p
er 1
00,0
00
C-136
0
100
200
300
400
500
85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 00 01 02 03 04 05
Year
Nu
mb
er o
f C
ases
Invasive Hib Disease Among Children Admitted to Hospitals Invasive Hib Disease Among Children Admitted to Hospitals in the IMPACTin the IMPACT†† Surveillance Network, 1985 – 2005 Surveillance Network, 1985 – 2005
††Immunization Monitoring Program, ActiveImmunization Monitoring Program, ActiveSource: Source: Can Med Assoc J.Can Med Assoc J. 1996;154:1041-1047 and 2005;172:53-6; 1996;154:1041-1047 and 2005;172:53-6;
Can Commun Dis Rep.Can Commun Dis Rep. 1998;24:105-108; 2000;26:93-96; 2001;27:149-150; 1998;24:105-108; 2000;26:93-96; 2001;27:149-150; Paediatr Child Health.Paediatr Child Health. 2005;10:314; and David Scheifele, IMPACT. 2005;10:314; and David Scheifele, IMPACT.
PENTACELIntroduced
C-137
Invasive Hib Disease, Children Aged <5 YearsInvasive Hib Disease, Children Aged <5 YearsIMPACT Surveillance Network, 2001 – 2005IMPACT Surveillance Network, 2001 – 2005
Only 34 cases during 2001 Only 34 cases during 2001 – – 20052005
Of these, 11 occurred among native children Of these, 11 occurred among native children (Aboriginal – First Nation and Inuit)(Aboriginal – First Nation and Inuit)– 2 unvaccinated2 unvaccinated
– 7 partially vaccinated (1 or 2 doses)7 partially vaccinated (1 or 2 doses)
– 2 received 3 doses (1 with recurrent 2 received 3 doses (1 with recurrent pneumonia history)pneumonia history)
Only 2 breakthrough cases during 5-year periodOnly 2 breakthrough cases during 5-year period
C-138
International Circumpolar Surveillance International Circumpolar Surveillance PHAC, Canada and CDC, USPHAC, Canada and CDC, US
CanadaCanada USUS
RegionsRegionsYukon, Northwest Territories, Yukon, Northwest Territories, Nunavut, northern Labrador Nunavut, northern Labrador
and Quebecand QuebecAlaskaAlaska
Total populationTotal population 137,000137,000 664,000664,000
Native populationNative population 75,000 (55%)75,000 (55%) 120,000 (18%)120,000 (18%)
SurveillanceSurveillance 5 years (2000-2004)5 years (2000-2004) 5 years (2002-2006)5 years (2002-2006)
VaccineVaccine PENTACELPENTACEL PRP-OMPPRP-OMP
Hib cases <5 y/o Hib cases <5 y/o 4 (3 Native)4 (3 Native) 7 (6 Native)7 (6 Native)
Ages (Doses)Ages (Doses) 1.6 mo (0)1.6 mo (0)
3.7 mo (unknown)3.7 mo (unknown)
3.9 mo (partial)3.9 mo (partial)
1.4 yr (partial)1.4 yr (partial)
0.4 mo (2)0.4 mo (2)
0.5 mo (0)0.5 mo (0)
0.8 mo (2)0.8 mo (2)
1.1 yr (2)1.1 yr (2)
2.4 yr (3)2.4 yr (3)
2.6 yr (3)2.6 yr (3)
3.6 yr (3)3.6 yr (3)
C-139
2007 NACI Recommendations for 2007 NACI Recommendations for Use of Combination Vaccines in CanadaUse of Combination Vaccines in Canada
““Combination vaccines against diphtheria, Combination vaccines against diphtheria, pertussis, polio, tetanus and…Hib infections pertussis, polio, tetanus and…Hib infections have become the standard for routine primary have become the standard for routine primary immunization of infants in Canada.”immunization of infants in Canada.”
““Like its monovalent constituent vaccines, Like its monovalent constituent vaccines, PENTACEL has been highly successful in PENTACEL has been highly successful in controlling these infectious diseases in Canada controlling these infectious diseases in Canada but has the additional benefit of fewer but has the additional benefit of fewer injections.”injections.”
NACI = Canadian National Advisory Committee on ImmunizationNACI = Canadian National Advisory Committee on ImmunizationCCDR 2007;33(ASC-1):1-14CCDR 2007;33(ASC-1):1-14
C-140
Conclusions: Effectiveness of PENTACEL Conclusions: Effectiveness of PENTACEL Against Pertussis and Invasive Hib DiseaseAgainst Pertussis and Invasive Hib Disease
9 years of clinical experience with more than 9 years of clinical experience with more than 12 million doses of PENTACEL in Canada12 million doses of PENTACEL in Canada
Multiple surveillance systems confirm very low Multiple surveillance systems confirm very low rates of pertussis and Hib disease rates of pertussis and Hib disease
PENTACEL provides sustained protection PENTACEL provides sustained protection against pertussis through 9 years of age against pertussis through 9 years of age
PENTACEL provides excellent protection PENTACEL provides excellent protection against invasive Hib diseaseagainst invasive Hib disease– Hib cases are rare among vaccinated children, Hib cases are rare among vaccinated children,
including high risk populationsincluding high risk populations
C-141
PENTACEL - AgendaPENTACEL - Agenda
IntroductionIntroduction Luc Kuykens, MD, MPHLuc Kuykens, MD, MPHVP Regulatory AffairsVP Regulatory Affairs
SafetySafety Luc Kuykens, MD, MPHLuc Kuykens, MD, MPHVP Regulatory AffairsVP Regulatory Affairs
Immunogenicity Immunogenicity Michael Decker, MD, MPH Michael Decker, MD, MPH VP Scientific and Medical AffairsVP Scientific and Medical Affairs
Canadian Post-Marketing Canadian Post-Marketing EffectivenessEffectiveness
Scott Halperin, MDScott Halperin, MDProfessor of Pediatrics Professor of Pediatrics Dalhousie University, Halifax, CanadaDalhousie University, Halifax, Canada
US PerspectiveUS Perspective David Greenberg, MDDavid Greenberg, MDDirector Scientific and Medical AffairsDirector Scientific and Medical Affairs
ConclusionConclusion Luc Kuykens, MD, MPHLuc Kuykens, MD, MPHVP Regulatory AffairsVP Regulatory Affairs
C-142
US PerspectiveUS Perspective
US ExperienceUS Experience– Pertussis and Hib epidemiology Pertussis and Hib epidemiology
– Comparison to Canadian experienceComparison to Canadian experience
Benefits of PENTACEL VaccineBenefits of PENTACEL Vaccine– Patient, healthcare provider, public healthPatient, healthcare provider, public health
– Immunization scheduleImmunization schedule
– Coverage rates and timelinessCoverage rates and timeliness
C-143
0
50
100
150
200
250
300
20 30 40 50 60 70 80 90 00Year
Ca
se
s (
Th
ou
sa
nd
s)
Epidemiology of Pertussis: Epidemiology of Pertussis: United States, 1922 United States, 1922 – – 20052005
CDC. CDC. MMWR.MMWR. 2002;51:73-76; 2002;51:73-76;CDC. Summary of notifiable diseases, US, 2003. Published Apr 22, 2005, MMWR 2003:52(54):72-76;CDC. Summary of notifiable diseases, US, 2003. Published Apr 22, 2005, MMWR 2003:52(54):72-76;CDC. Summary of notifiable diseases, US, 2004. Published June 16, 2006, MMWR 2004:53(53):19;CDC. Summary of notifiable diseases, US, 2004. Published June 16, 2006, MMWR 2004:53(53):19;CDC. CDC. MMWR.MMWR. 2005;55:890. 2005;55:890.
Epidemiology of Pertussis; Canada, 1924-2000
C-144
Pertussis Incidence, US, 2005Pertussis Incidence, US, 2005
Rates per 100,000 persons; Rates per 100,000 persons; National Center for Immunization and Respiratory Diseases, CDC. Pertussis Surveillance Reports for 2005.National Center for Immunization and Respiratory Diseases, CDC. Pertussis Surveillance Reports for 2005.
0
10
20
30
40
50
160
<6 mos 6-11 mos 1-4 yrs 5-9 yrs 10-19 yrs 20+ yrs
Inci
den
ce p
er 1
00,0
00
140
C-145
00
0.10.1
0.20.2
0.30.3
0.40.4
0.50.5
9494 9595 9696 9797 9898 9999 0000 0101 0202 0303 0404 0505
YearYear
Hib: Invasive Disease in US Children <5 Years Hib: Invasive Disease in US Children <5 Years National Data, 1994 National Data, 1994 – – 20052005
Note: Rates per 100,000 persons; Only cases confirmed as type b are shown.Note: Rates per 100,000 persons; Only cases confirmed as type b are shown.Source: Source: MMWRMMWR 1995;44:545-50; 1996;45:901-6; 1998;47:993-8; 2001;50:48; 2002:51:16; 2002;51:234-7; 2004;53:691; 1995;44:545-50; 1996;45:901-6; 1998;47:993-8; 2001;50:48; 2002:51:16; 2002;51:234-7; 2004;53:691; 2005;54:775; and 2006;55:887. 2005;54:775; and 2006;55:887.
Rat
e p
er 1
00,0
00R
ate
per
100
,000
C-146
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
94 95 96 97 98 99 00 01 02 03 04 05
Year
Inci
den
ce R
ate
Hib: Invasive Disease in US Children <5 Years Hib: Invasive Disease in US Children <5 Years ABCs Data, 1994 ABCs Data, 1994 – – 20052005
Note: Rates per 100,000 persons; Note: Rates per 100,000 persons; 2005 data are provisional2005 data are provisionalSource: http://www.cdc.gov/ncidod/dbmd/abcs/reports.htmSource: http://www.cdc.gov/ncidod/dbmd/abcs/reports.htm
0
5
10
15
20
25
94 95 96 97 98 99 00 01 02 03 04 05Year
Ca
se
s
IMPACT Surveillance NetworkIMPACT Surveillance Network
C-147
0
10
20
30
40
50
60
96 97 98 99 00 01 02 03 04 05
Year
Per
cen
t o
f M
arke
t S
har
eActHIB Vaccine Market Share in the US, ActHIB Vaccine Market Share in the US, 1996 1996 – – 2005 2005
Note: Assumed market of 15.2 million Hib conjugate vaccine doses per year; includes TriHIBitNote: Assumed market of 15.2 million Hib conjugate vaccine doses per year; includes TriHIBit ®®..Source: Data on file, sanofi pasteur.Source: Data on file, sanofi pasteur.
C-148
Summary of US and Canadian ExperiencesSummary of US and Canadian Experiences
Pertussis epidemiology is similar in US and Canada Pertussis epidemiology is similar in US and Canada – In Canada, PENTACEL has led to sustained protection against In Canada, PENTACEL has led to sustained protection against
pertussis through 9 years of agepertussis through 9 years of age
The epidemiology of invasive Hib disease is similar in The epidemiology of invasive Hib disease is similar in US and CanadaUS and Canada– ActHIB is the dominant Hib vaccine used in the USActHIB is the dominant Hib vaccine used in the US
– ActHIB, in PENTACEL, is the exclusive Hib vaccine used ActHIB, in PENTACEL, is the exclusive Hib vaccine used in Canada in Canada
In light of these data, PENTACEL is expected to perform In light of these data, PENTACEL is expected to perform as well in US as it has in Canada as well in US as it has in Canada
C-149
2007 Recommended Childhood Immunization 2007 Recommended Childhood Immunization Schedule: Birth Schedule: Birth – 18 Months– 18 Months
C-150
ACIP, AAP, AAFP Recommendations:ACIP, AAP, AAFP Recommendations:Combination VaccinesCombination Vaccines
““To minimize the number of injections children To minimize the number of injections children receive, parenteral combination vaccines receive, parenteral combination vaccines should be used, if licensed and indicated for the should be used, if licensed and indicated for the patient’s age, instead of their equivalent patient’s age, instead of their equivalent component vaccines.”component vaccines.”
““The use of licensed combination vaccines is The use of licensed combination vaccines is preferred over separate injection of their preferred over separate injection of their equivalent component vaccines.”equivalent component vaccines.”
Centers for Disease Control and Prevention (CDC). Centers for Disease Control and Prevention (CDC). MMWR.MMWR. 1999;48(No. RR-5):1-2. 1999;48(No. RR-5):1-2.
C-151
CDC: Timeliness of Childhood Immunizations, CDC: Timeliness of Childhood Immunizations, United StatesUnited States
2003 National Immunization Survey (n=14,810)2003 National Immunization Survey (n=14,810)
Only 17% of 24-35 month old children were Only 17% of 24-35 month old children were immunized on time for 6 vaccinesimmunized on time for 6 vaccines
Undervaccinated by mean of 172 daysUndervaccinated by mean of 172 days
37% undervaccinated >6 months for 37% undervaccinated >6 months for 1 vaccine1 vaccine– IPV IPV 9% 9%
– DTaP DTaP 16% 16%
– HibHib 21%21%
Luman et al. Luman et al. JAMA.JAMA. 2006;293:1204-11. 2006;293:1204-11.
C-152
0
20
40
60
80
100
4 DTaP 3 Hep B 3 IPV
Per
cen
t o
f C
hil
dre
n
Separate Vaccine Cohort (n=1990) Combination Cohort (n=1990)
Improved Coverage Rates, 2 Years of Age Improved Coverage Rates, 2 Years of Age Georgia Medicaid 2003Georgia Medicaid 2003
Marshall et al. 40th National Immunization Conference, Atlanta, GA, March 2006.
All comparisons, P<0.001
C-153
Improved Coverage Rates, 15 Months of Age Improved Coverage Rates, 15 Months of Age Germany, 1996 Germany, 1996 –– 2003 2003
00
1010
2020
3030
4040
5050
Per
cen
t F
ull
y Im
mu
niz
ed
Per
cen
t F
ull
y Im
mu
niz
ed
by
15 M
on
ths
of
Ag
eb
y 15
Mo
nth
s o
f A
ge
HibHib IPVIPV Hepatitis BHepatitis B
MonovalentMonovalent19961996
DTaP-HibDTaP-Hib1997-19981997-1998
DTaP-IPV-HibDTaP-IPV-Hib1998-20001998-2000
DTaP-IPV-Hib-HepBDTaP-IPV-Hib-HepB2001-20032001-2003
Kailies et al. Kailies et al. Pediatr Infect Dis J.Pediatr Infect Dis J. 2006;25:507-12. 2006;25:507-12.N=2701 children with immunization booklets availableN=2701 children with immunization booklets available
C-154
2007 Recommended Childhood Immunization 2007 Recommended Childhood Immunization Schedule: Birth Schedule: Birth – 18 Months– 18 Months
C-155
Reduction of the Number of Injections Through Reduction of the Number of Injections Through 18 Months of Age with Combination Vaccines18 Months of Age with Combination Vaccines
23
-10
-5
0
5
10
15
20
25
Total # of Shots
Single Entity
20
-3
Comvax
18
-5
Pediarix
16
-7
PENTACEL
22
-1
TriHIBit
Shot Reduction vs Single Entity
C-156
PENTACEL: First Candidate DTaP-IPV-Hib PENTACEL: First Candidate DTaP-IPV-Hib Combination Vaccine in the USCombination Vaccine in the US
Patient BenefitsPatient Benefits– Maximum shot reductionMaximum shot reduction
– Safety profile encourages complianceSafety profile encourages compliance
Healthcare Provider BenefitsHealthcare Provider Benefits– Optimizes implementation of immunization recommendationsOptimizes implementation of immunization recommendations
– Simplifies administrationSimplifies administration
Public Health BenefitsPublic Health Benefits– Expected to improve vaccination coverage rates and timelinessExpected to improve vaccination coverage rates and timeliness
– Facilitates optimal HepB scheduleFacilitates optimal HepB schedule
– Improves combination vaccine supply for infant seriesImproves combination vaccine supply for infant series
C-157
PENTACEL - AgendaPENTACEL - Agenda
IntroductionIntroduction Luc Kuykens, MD, MPHLuc Kuykens, MD, MPHVP Regulatory AffairsVP Regulatory Affairs
SafetySafety Luc Kuykens, MD, MPHLuc Kuykens, MD, MPHVP Regulatory AffairsVP Regulatory Affairs
Immunogenicity Immunogenicity Michael Decker, MD, MPH Michael Decker, MD, MPH VP Scientific and Medical AffairsVP Scientific and Medical Affairs
Canadian Post-Marketing Canadian Post-Marketing ExperienceExperience
Scott Halperin, MDScott Halperin, MDProfessor of Pediatrics Professor of Pediatrics Dalhousie University, Halifax, CanadaDalhousie University, Halifax, Canada
US ExperienceUS Experience David Greenberg, MDDavid Greenberg, MDDirector Scientific and Medical AffairsDirector Scientific and Medical Affairs
ConclusionConclusion Luc Kuykens, MD, MPHLuc Kuykens, MD, MPHVP Regulatory AffairsVP Regulatory Affairs
C-158
PENTACEL Clinical Safety ConclusionsPENTACEL Clinical Safety Conclusions
Safety profile of PENTACEL similar to that of Safety profile of PENTACEL similar to that of separate administration of US standard of care separate administration of US standard of care vaccines (Daptacel, IPOL, and ActHIB)vaccines (Daptacel, IPOL, and ActHIB)
PENTACEL is safe when administered alone or PENTACEL is safe when administered alone or concomitantly with other age-recommended concomitantly with other age-recommended vaccinesvaccines
C-159
PENTACEL Immunogenicity ConclusionsPENTACEL Immunogenicity Conclusions
PENTACEL efficacy against Pertussis can be PENTACEL efficacy against Pertussis can be concluded based on favorable serological concluded based on favorable serological comparison to the Sweden I Efficacy Trialcomparison to the Sweden I Efficacy Trial
PENTACEL produced Hib GMTs and PENTACEL produced Hib GMTs and seroprotection rates that were comparable to seroprotection rates that were comparable to separately administered US standard of separately administered US standard of care vaccinescare vaccines
Immune responses were similar when PENTACEL Immune responses were similar when PENTACEL was administered alone or concomitantly with was administered alone or concomitantly with other vaccinesother vaccines
C-160
PENTACEL BenefitsPENTACEL Benefits
Proven safety record after 9 years of exclusive use Proven safety record after 9 years of exclusive use in Canadain Canada
Proven effective in controlling pertussis and Hib Proven effective in controlling pertussis and Hib disease in Canadadisease in Canada– Similar epidemiology of pertussis and Hib in Canada and US Similar epidemiology of pertussis and Hib in Canada and US
predicts similar success with PENTACELpredicts similar success with PENTACEL
Patient benefits with maximum shot reductionPatient benefits with maximum shot reduction
Provider benefits with simplified administrationProvider benefits with simplified administration
Public health benefits through potential improvement of Public health benefits through potential improvement of vaccination timeliness and coveragevaccination timeliness and coverage
C-161
PENTACELPENTACEL®®
Diphtheria and Tetanus Toxoids and Acellular Pertussis Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus Vaccine and HaemophilusAdsorbed, Inactivated Poliovirus Vaccine and Haemophilus b b
Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib Combined)(DTaP-IPV/Hib Combined)
Vaccine and Related Biological Products Vaccine and Related Biological Products Advisory CommitteeAdvisory Committee
January 25, 2007January 25, 2007
The vaccines business of sanofi-aventis GroupThe vaccines business of sanofi-aventis Group